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Foreword 
 
The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 
2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in 
the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The 
publications and other scientific activities included in the evaluation covered the years 2005–2010. 
The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a 
critical mass with university-level impact, the number of members was set to range from 20 to 120. The 
RCs were required to contain researchers in all stages of their research career, from doctoral students to 
principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary 
evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to 
participate in two communities in certain cases, and 72 of them used this opportunity and participated in 
two RCs. 
This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim 
of the evaluation was not to assess individual performance but a community with shared aims and 
researcher-training activities. The RCs were able to choose among five different categories that 
characterised the status and main aims of their research. The steering group considered the process of 
applying to participate in the evaluation to be important, which lead to the establishment of these 
categories. In addition, providing a service for the RCs to enable them to benchmark their research at the 
global level was a main goal of the evaluation. 
The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms 
and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The 
compilation covered scientific and other publications as well as certain areas of scientific activities. During 
the process, the RCs were asked to check the list of publications and other scientific activities and make 
corrections if needed. These TUHAT compilations are public and available on the evaluation project sites 
of each RC in the TUHAT-RIS. 
In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric 
analyses from the articles included in the Web of Science (WoS). This was done on University and RC 
levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the 
Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 
66 RCs representing the humanities and social sciences. 
The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about 
the organisation of doctoral studies at the University of Helsinki. This and other documents describing the 
University and the Finnish higher education system were provided to the panellists. 
The panel feedback for each RC is unique and presented as an entity. The first collective evaluation 
reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all 
panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to 
complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, 
doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for 
participation in the evaluation. Panellists used the international level as a point of comparison in the 
evaluation. Scoring was not expected to go along with a preset deviation. 
Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 
September to 13 September or from 18 September to 20 September 2011). In these meetings the panels 
also examined the deviations among the scores and finalised the draft reports together. 
The current RC-specific report deals shortly with the background of the evaluation and the terms of 
participation. The main evaluation feedback is provided in the evaluation report, organised according to 
the evaluation questions. The original material provided by the RCs for the panellists has been attached to 
these documents. 
 
 
 
 
 
 
 
 
 
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your 
participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully 
acknowledged by the University. We wish that you find this panel feedback useful in many ways. The 
bibliometric profiles may open a new view on your publication forums and provide a perspective for 
discussion on your choice of forums. We especially hope that this evaluation report will help you in setting 
the future goals of your research. 
 
Johanna Björkroth 
Vice-Rector 
Chair of the Steering Group of the Evaluation 
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Panel members 
CHAIR 
Professor Lorenz Poellinger 
Cancer biology, cell and molecular biology 
Karolinska Institute, Sweden 
 
VICE-CHAIR 
Professor Cornelia van Duijn 
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Erasmus Medical Centre, the Netherlands 
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Molecular cell biology, cell adhesion, cancer biology 
University of Turku, VTT Technical Research Centre, Finland 
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University of Turku, Finland 
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Neuroscience, neurophysiology 
University of Münster, Germany 
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preventive medicine 
Karolinska Institute, Sweden 
 
Professor Peter York 
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The panel, independently, evaluated all the submitted material and was responsible for the 
feedback of the RC-specific reports. The panel members were asked to confirm whether they had any 
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discussion and report writing. 
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Dr Seppo Saari, Doc., Senior Adviser in Evaluation, was responsible for the entire 
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reports. 
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Mrs Aija Kaitera, Project Manager of TUHAT-RIS served the project ex officio 
providing the evaluation project with the updated information from TUHAT-RIS. 
The TUHAT office assisted in mapping the publications with CWTS/University of 
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MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. She also assisted the UH/Library analyses. 
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the 
publications for the evaluation. 
 
HELSINKI UNIVERSITY LIBRARY 
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sciences and in other fields of sciences where CWTS analyses were not 
applicable. 
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Acronyms and abbreviations applied in the report 
 
External competitive funding 
AF – Academy of Finland 
TEKES - Finnish Funding Agency for Technology and Innovation  
EU - European Union 
ERC - European Research Council 
International and national foundations 
FP7/6 etc. /Framework Programmes/Funding of European Commission 
 
Evaluation marks 
Outstanding (5) 
Excellent  (4) 
Very Good  (3) 
Good  (2) 
Sufficient  (1) 
 
Abbreviations of Bibliometric Indicators 
P - Number of publications 
TCS – Total number of citations 
MCS - Number of citations per publication, excluding self-citations 
PNC - Percentage of uncited publications 
MNCS - Field-normalized number of citations per publication 
MNJS - Field-normalized average journal impact 
THCP10 - Field-normalized proportion highly cited publications (top 10%) 
INT_COV - Internal coverage, the average amount of references covered by the WoS 
WoS – Thomson Reuters Web of Science Databases 
 
Participation category 
Category 1. The research of the participating community represents the international cutting edge in its 
field. 
Category 2. The research of the participating community is of high quality, but the community in its 
present composition has yet to achieve strong international recognition or a clear break-through. 
Category 3. The research of the participating community is distinct from mainstream research, and the 
special features of the research tradition in the field must be considered in the evaluation. 
Category 4. The research of the participating community represents an innovative opening. 
Category 5. The research of the participating community has a highly significant societal impact. 
 
Research focus areas of the University of Helsinki 
Focus area 1: The basic structure, materials and natural resources of the physical world 
Focus area 2: The basic structure of life 
Focus area 3: The changing environment – clean water 
Focus area 4: The thinking and learning human being 
Focus area 5: Welfare and safety 
Focus area 6: Clinical research 
Focus area 7: Precise reasoning 
Focus area 8: Language and culture 
Focus area 9: Social justice 
Focus area 10: Globalisation and social change 
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1 Introduction to the Evaluation 
1.1 RC-specific evaluation reports 
The participants in the evaluation of research and doctoral training were Researcher Communities 
(hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the 
evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the 
Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their 
compositions should be considered well-established or new. 
It is essential to emphasise that the evaluation combines both meta-evaluation1 and traditional 
research assessment exercise and its focus is both on the research outcomes and procedures associated 
with research and doctoral training. The approach to the evaluation is enhancement-led where self-
evaluation constituted the main information. The answers to the evaluation questions formed together 
with the information of publications and other scientific activities an entity that was to be reviewed as a 
whole. 
The present evaluation recognizes and justifies the diversity of research practices and publication 
traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with 
low volumes or research distinct from mainstream research. It is challenging to expose the diversity of 
research to fair comparison. To understand the essence of different research practices and to do justice to 
their diversity was one of the main challenges of the present evaluation method. Understanding the 
divergent starting points of the RCs demanded sensitivity from the evaluators. 
1.2 Aims and objectives in the evaluation 
The aims of the evaluation are as follows: 
 to improve the level of research and doctoral training at the University of Helsinki and to raise 
their international profile in accordance with the University’s strategic policies. The improvement 
of doctoral training should be compared to the University’s policy.2 
 to enhance the research conducted at the University by taking into account the diversity, 
originality, multidisciplinary nature, success and field-specificity, 
 to recognize the conditions and prerequisites under which excellent, original and high-impact 
research is carried out, 
 to offer the academic community the opportunity to receive topical and versatile international 
peer feedback, 
 to better recognize the University’s research potential. 
 to exploit the University’s TUHAT research information system to enable transparency of 
publishing activities and in the production of reliable, comparable data. 
1.3 Evaluation method 
The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to 
provide useful information for the enhancement of research and doctoral training of the participating RCs. 
The comparison should take into account each field of science and acknowledge their special character. 
                                                                
1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation 
questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses. 
2
 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.  
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The comparison produced information about the present status and factors that have lead to success. Also 
challenges in the operations and outcomes were recognized. 
The evaluation approach has been designed to recognize better the significance and specific nature of 
researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one 
of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent 
ones. Thus the views of various fields of research can be described and research arising from various 
starting points understood better. The doctoral training is integrated into the evaluation as a natural 
component related to research. Operational processes of doctoral training are being examined in the 
evaluation. 
 
Five stages of the evaluation method were: 
1. Registration – Stage 1 
2. Self-evaluation – Stage 2 
3. TUHAT3 compilations on publications and other scientific activities4 
4. External evaluation 
5. Public reporting 
1.4 Implementation of the external evaluation 
Five Evaluation Panels 
Five evaluation panels consisted of independent, renowned and highly respected experts. The main 
domains of the panels are: 
1. biological, agricultural and veterinary sciences 
2. medicine, biomedicine and health sciences 
3. natural sciences 
4. humanities 
5. social sciences 
The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on 
the suggestions of faculties and independent institutes. Besides leading the work of the panel, an 
additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar 
approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam. 
The panel compositions were nominated by the Rector of the University 27 April 2011. The participating 
RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller 
number of panellists as compared to the previous evaluations was the character of the evaluation as a 
meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated 
answers to the evaluation questions, tables and compilations of publications, other scientific activities, 
bibliometrics and comparable analyses. 
 
The panel meetings were held in Helsinki: 
 On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, 
biomedicine and health sciences and (3) natural sciences.  
 On 18–20 September 2011: (4) humanities and (5) social sciences. 
  
                                                                
3 TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki 
4 Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and 
networks and public appearances. 
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1.5 Evaluation material 
The main material in the evaluation was the RCs’ self-evaluations that were qualitative in character and 
allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned. 
The present evaluation is exceptional at least in the Finnish context because it is based on both the 
evaluation documentation (self-evaluation questions, publications and other scientific activities) and the 
bibliometric reports. All documents were delivered to the panellists for examination. 
Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences 
when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for 
Science and Technology Studies, University of Leiden, cover only the publications that include WoS 
identification in the TUHAT-RIS. 
Traditional bibliometrics are seldom relevant in humanities and social sciences because the 
international comparable databases do not store every type of high quality research publications, such as 
books and monographs and scientific journals in other languages than English. The Helsinki University 
Library has done analysis to the RCs, if their publications were not well represented in the Web of Science 
databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) 
– it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-
specific bibliometric reports are attached at the end of each report. 
The panels were provided with the evaluation material and all other necessary background information, 
such as the basic information about the University of Helsinki and the Finnish higher education system. 
 
Evaluation material 
1. Registration documents of the RCs for the background information 
2. Self evaluation material – answers to the evaluation questions 
3. Publications and other scientific activities based on the TUHAT RIS: 
3.1. statistics of publications 
3.2. list of publications 
3.3. statistics of other scientific activities 
3.4. list of other scientific activities 
4. Bibliometrics and comparable analyses: 
4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web 
of Science publications (CWTS/University of Leiden) 
4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and 
social sciences 
5. University level survey on doctoral training (August 2011) 
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University 
of Leiden 
 
Background material 
 
University of Helsinki 
- Basic information about the University of the Helsinki 
- The structure of doctoral training at the University of Helsinki 
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005 
 
The Finnish Universities/Research Institutes 
- Finnish University system 
- Evaluation of the Finnish National Innovation System 
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 
9/09. 
 
The evaluation panels were provided also with other relevant material on request before the meetings in 
Helsinki. 
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1.6 Evaluation questions and material 
The participating RCs answered the following evaluation questions which are presented according to the 
evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For 
giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line 
with the evaluation questions: 
 
1. Focus and quality of the RC’s research 
 Description of 
- the RC’s research focus. 
- the quality of the RC’s research (incl. key research questions and results) 
- the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data 
(provided by University of Leiden and the Helsinki University Library) 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
2. Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
- recruitment and selection of doctoral candidates 
- supervision of doctoral candidates 
- collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
- good practises and quality assurance in doctoral training 
- assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
3. The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with 
public, private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral 
training. 
The additional material: TUHAT compilation of the RC’s other scientific activities. 
A written feedback from the aspects of: societal impact, national and international collaboration, 
innovativeness 
 
  Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
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4. International and national (incl. intersectoral) research collaboration and researcher mobility 
 Description of  
- the RC’s research collaborations and joint doctoral training activities 
- how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and 
researcher mobility, and the actions planned for their development. 
A written feedback from the aspects of: scientific quality, national and international collaboration 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
5. Operational conditions  
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the 
actions planned for their development. 
A written feedback from the aspects of: processes and good practices related to leadership and 
management 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
6. Leadership and management in the researcher community 
 Description of 
- the execution and processes of leadership in the RC 
- how the management-related responsibilities and roles are distributed in the RC 
- how the leadership- and management-related processes support 
- high quality research 
- collaboration between principal investigators and other researchers in the RC 
the RC’s research focus 
- strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and 
the actions planned for developing the processes 
 
7. External competitive funding of the RC 
 The RCs were asked to provide information of such external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The 
Finnish Funding Agency for Technology and Innovation , EU, ERC, foundations, other national funding 
organisations, other international funding organisations), and 
2)The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
 
Competitive funding reported in the text is also to be considered when evaluating this point. 
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, 
innovativeness, future significance 
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
8. The RC’s strategic action plan for 2011–2013 
 RC’s description of their future perspectives in relation to research and doctoral training. 
A written feedback from the aspects of: scientific quality, scientific significance, societal Impact, processes 
and good practices related to leadership and management, national and international collaboration, 
innovativeness, future significance 
 Strengths 
 Areas of development 
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 Other remarks 
 Recommendations 
 
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) 
 
The RC’s fitness to the chosen participation category 
A written feedback evaluating the RC’s fitness to the chosen participation category  
 Strengths 
 Areas of development 
 Other remarks 
 Recommendations 
 
Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1) 
 
10. Short description of how the RC members contributed the compilation of the stage 2 material 
Comments on the compilation of evaluation material 
 
11. How the UH’s focus areas are presented in the RC’s research? 
Comments if applicable 
 
12. RC-specific main recommendations based on the previous questions 1–11 
 
13. RC-specific conclusions 
1.7 Evaluation criteria 
The panellists were expected to give evaluative and analytical feedback to each evaluation question 
according to their aspects in order to describe and justify the quality of the submitted material. In 
addition, the evaluation feedback was asked to be pointed out the level of the performance according to 
the following classifications: 
 outstanding  (5) 
 excellent  (4) 
 very good  (3) 
 good   (2) 
 sufficient  (1) 
 
Evaluation according to the criteria was to be made with thorough consideration of the entire 
evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to 
classify their written feedback into one of the provided levels (the levels included respective descriptions, 
‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the 
integers and not rounding up the decimals by the editors. 
 
Description of criteria levels 
Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Outstandingly strong research, also from international perspective. Attracts great international 
interest with a wide impact, including publications in leading journals and/or monographs published 
by leading international publishing houses. The research has world leading qualities. The research 
focus, key research questions scientific significance, societal impact and innovativeness are of 
outstanding quality. 
In cases where the research is of a national character and, in the judgement of the evaluators, should 
remain so, the concepts of ”international attention” or ”international impact” etc. in the grading 
criteria above may be replaced by ”international comparability”. 
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Operations and procedures are of outstanding quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are in 
alignment with the documentation. The ambition to develop the community together is of 
outstanding quality. 
Excellent quality of procedures and results (4) 
Research of excellent quality. Typically published with great impact, also internationally. Without 
doubt, the research has a leading position in its field in Finland. 
Operations and procedures are of excellent quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of excellent quality. 
Very good quality of procedures and results (3) 
The research is of such very good quality that it attracts wide national and international attention. 
Operations and procedures are of very good quality, transparent and shared in the community. The 
improvement of research and other efforts are documented and operations and practices are to 
large extent in alignment with the documentation. The ambition to develop the community together 
is of very good quality. 
Good quality of procedures and results (2) 
Good research attracting mainly national attention but possessing international potential, 
extraordinarily high relevance may motivate good research. 
Operations and procedures are of good quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to large extent in alignment with the documentation. The ambition to develop the 
community together is of good quality. 
Sufficient quality of procedures and results (1) 
In some cases the research is insufficient and reports do not gain wide circulation or do not have 
national or international attention. Research activities should be revised. 
Operations and procedures are of sufficient quality, shared occasionally in the community. The 
improvement of research and other efforts are occasionally documented and operations and 
practices are to some extent in alignment with the documentation. The ambition to develop the 
community together is of sufficient quality. 
 
Question 2 – DOCTORAL TRAINING 
Question 3 – SOCIETAL IMPACT 
Question 4 – COLLABORATION 
 
Classification: Criteria (level of procedures and results) 
Outstanding quality of procedures and results (5) 
Procedures are of outstanding quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are in alignment with the 
documentation. The ambition to develop the community together is of outstanding quality. The 
procedures and results are regularly evaluated and the feedback has an effect on the planning. 
Excellent quality of procedures and results (4) 
Procedures are of excellent quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of excellent quality. The 
procedures and outcomes are evaluated and the feedback has an effect on the planning. 
Very good quality of procedures and results (3) 
Procedures are of very good quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
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management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of very good quality. 
Good quality of procedures and results (2) 
Procedures are of good quality, shared occasionally in the community. The practices and quality of 
doctoral training/societal impact/international and national collaboration/leadership and 
management are documented and operations and practices are to large extent in alignment with the 
documentation. The ambition to develop the community together is of good quality. 
Sufficient quality of procedures and results (1) 
Procedures are of sufficient quality, transparent and shared in the community. The practices and 
quality of doctoral training/societal impact/international and national collaboration/leadership and 
management are occasionally documented and operations and practices are to some extent in 
alignment with the documentation. The ambition to develop the community together is of sufficient 
quality. 
 
Question 9 – CATEGORY 
Participation category – fitness for the category chosen 
The choice and justification for the chosen category below should be reflected in the RC’s responses to the 
evaluation questions 1–8. 
1. The research of the participating community represents the international cutting edge in its field. 
2. The research of the participating community is of high quality, but the community in its present 
composition has yet to achieve strong international recognition or a clear break-through. 
3. The research of the participating community is distinct from mainstream research, and the special 
features of the research tradition in the field must be considered in the evaluation. The research is 
of high quality and has great significance and impact in its field. However, the generally used 
research evaluation methods do not necessarily shed sufficient light on the merits of the 
research.  
4. The research of the participating community represents an innovative opening. A new opening can 
be an innovative combination of research fields, or it can be proven to have a special social, 
national or international demand or other significance. Even if the researcher community in its 
present composition has yet to obtain proof of international success, its members can produce 
convincing evidence of the high level of their previous research. 
5. The research of the participating community has a highly significant societal impact. The 
participating researcher community is able to justify the high social significance of its research. 
The research may relate to national legislation, media visibility or participation in social debate, 
or other activities promoting social development and human welfare. In addition to having 
societal impact, the research must be of a high standard. 
 
An example of outstanding fitness for category choice (5) 5 
The RC’s representation and argumentation for the chosen category were convincing. The RC recognized 
its real capacity and apparent outcomes in a wider context to the research communities. The specific 
character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the 
category. 
 
 Outstanding  (5) 
 Excellent  (4) 
 Very good  (3) 
 Good   (2) 
 Sufficient  (1) 
The above-mentioned definition of outstanding was only an example in order to assist the panellists in 
the positioning of the classification. There was no exact definition for the category fitness. 
                                                                
5 The panels discussed the category fitness and made the final conclusions of the interpretation of it. 
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1.8 Timetable of the evaluation 
The main timetable of the evaluation: 
1. Registration   November 2010 
2. Submission of self-evaluation materials  January–February 2011 
3. External peer review    May–September 2011 
4. Published reports    March–April 2012 
- University level public report 
- RC specific reports 
 
The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary 
results were available for the planning of the following strategy period in late autumn 2011. The evaluation 
reports will be published in March/April 2012. More detailed time schedule is published in the University 
report. 
1.9 Evaluation feedback – consensus of the entire panel 
The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the 
draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists 
on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft 
reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued 
working and finalised the reports before the end of November 2011. The final RC-specific reports are the 
consensus of the entire panel. 
The evaluation reports were written by the panels independently. During the editing process, the 
evaluation office requested some clarifications from the panels when necessary. The tone and style in the 
reports were not harmonized in the editing process. All the reports follow the original texts written by the 
panels as far as it was possible. 
The original evaluation material of the RCs, provided for the panellists is attached at the end of the 
report. It is essential to notice that the exported lists of publications and other scientific activities depend 
how the data was stored in the TUHAT-RIS by the RCs. 
  
14 
 
  
 
 
15 
 
2 Evaluation feedback 
2.1 Focus and quality of the RC’s research 
 Description of 
 the RC’s research focus 
 the quality of the RC’s research (incl. key research questions and results) 
 the scientific significance of the RC’s research in the research field(s) 
 Identification of the ways to strengthen the focus and improve the quality of the RC’s research 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness 
 
PARTICLE, composed of 45 researchers plus 10 licentiate candidates for industrial pharmacy, with 3 PIs 
including Professor Juppo who was appointed to the new chair of Industrial Pharmacy in 2007, is based in 
the Faculty of Pharmacy. The research focuses of the three groups in the RC are distinctly different with 
some overlap of areas of study which enables collaboration and doctoral co-supervision. Current research 
is focussed on solid dosage forms of medicines with specific activity in solid state materials science and 
formulation design and functionalized nanotechnological controlled release forms, targeting studies at the 
molecular level to provide mechanistic understanding of material behaviour during formulation and 
processing. Such understanding is important in the optimisation of the design and processing of solid 
dosage forms for therapeutic performance, the work is distinct from other RCs activities, and the 
researchers are making important contributions in this field. With the immanent contributions to new 
research field, a higher participation in IP protection (mostly patents) should be envisaged. 
Trends and field-averaged publication figures from the bibliographic analyses show a creditable annual 
publication record (averaging approximately 25 papers/year) with average values for MNCS and MNJS. 
Whilst 10 of the 142 papers were published in RC regarded high impact value journals, this aspect of 
publication policy should be addressed by the RC, with discussion and planned action to increase this 
number and proportion. The RC has a strong record of output of PhD theses (22 during the evaluation 
period) with 6 doctoral graduates gaining professorships in Finland and overseas. 
Future research plans propose additional collaboration with top universities and EU consortia, and a 
newly formed international cluster in the focussed field of study of the RC. As mentioned above, the 
targeting of appropriate journals with high impact for publishing outputs is, and should be, reviewed to 
raise the international profile and reputation of the RC. 
Overall, the RC operates at a high standard nationally with a focused research agenda with impressive 
doctoral programme and output. Attention needs to be given to elevating the international standing. 
Appropriate plans are outlined which will help to address this requirement. 
Numeric evaluation: 3 (Very good) 
2.2 Practises and quality of doctoral training 
 Organising of the doctoral training in the RC. Description of the RC’s principles for: 
 recruitment and selection of doctoral candidates 
 supervision of doctoral candidates 
 collaboration with faculties, departments/institutes, and potential graduate schools/doctoral 
programmes 
 good practises and quality assurance in doctoral training 
 assuring of good career perspectives for the doctoral candidates/fresh doctorates 
 Identification of the RC’s strengths and challenges related to the practises and quality of doctoral 
training, and the actions planned for their development. 
16 
 
 Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral 
dissertations 
ASPECTS: Processes and good practices related to leadership and management 
 
The recruitment and supervisory processes for doctoral students are in accord with good practice and 
sound procedures. All doctoral students are closely mentored and their progress is monitored during 
studies via a supervisory panel headed by a professor. Most students are members of the Graduate School 
of Pharmaceutical Research, and training complies with high quality Graduate School instructions and 
governance. 
The RC has participated in numerous research and training programmes with academia in Helsinki and 
other universities in Finland, and the international collaborations of RC staff provide opportunities for 
periods of overseas study for students which is encouraged, as is participation at international 
conferences. 
The number of completed PhD theses during the period of evaluation (22) is impressive and the RC 
should be congratulated on this figure. Nevertheless attention should be given promptly to several 
identified challenges, especially to greater interaction between students and research staff in the three 
groups in the RC and in initiating joint doctoral training programmes. 
Some general problem-oriented teaching studies based on theoretical or practical components with 
large overlap within the different groups of this RC may help to increase the information exchange and 
cross-interactions. 
Numeric evaluation: 3 (Very good) 
2.3 The societal impact of research and doctoral training 
 Description on how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector). 
 Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training. 
 Additional material: TUHAT compilation of the RC’s other scientific activities. 
ASPECTS: Societal impact, national and international collaboration, innovativeness 
 
The major societal impact as identified by the RC is the development, formulation and manufacturing of 
medicines, together with industrial collaboration and the education of postgraduate students (PhD and 
MSc). With the RC providing the major source of training and academic know-how in the field of 
pharmaceutical development in Finland, it is important that this facility and resource is recognised and 
supported. 
Through careful pre-evaluation of suitable research programmes, the industrial links can augment 
relevance and timeliness to the RC research activity and an appropriate balance between fundamental and 
applied work is necessary. However, it is not clear how decisions on how this balance is debated, agreed 
and reached across the RC, and clear guidelines should be established if not already in place. Despite the 
clearly seen need of pharmaceutical industry for IP protection some new models should be tested, e.g. 
open innovation, and then may be taken as new examples for effective and productive co-operations. 
The RC has communicated their findings and knowledge gained via the regular and appropriate 
channels – publications, conference participation, and a number of invited and plenary lectures at 
international symposia. Increasing the frequency of such invited presentations would also help to raise the 
international profile of the RC. Contributions have also been made to other media formats, as well as 
participation in national and international professional and scientific committees, and editorial and 
reviewing activity for a range of scientific journals. 
The RC also comments correctly to the need to incorporate ethical aspects, such as environmental 
impact, into account in research and educational strategies. 
Numeric evaluation: 3 (Very good) 
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2.4 International and national (incl. intersectoral) research 
collaboration and researcher mobility 
 Description of  
 the RC’s research collaborations and joint doctoral training activities 
 how the RC has promoted researcher mobility 
 Identification of the RC’s strengths and challenges related to research collaboration and researcher 
mobility, and the actions planned for their development. 
ASPECTS: Scientific quality, national and international collaboration 
 
The RC has an extensive portfolio of national and international collaboration in research and doctoral 
training including multidisciplinary projects. Funding is generally via TEKES, Academy of Finland, EU and 
industry. 
The RC benefits from a large number of international exchanges for researchers and students and has 
attracted numerous postgraduate students and researchers from overseas during the period of 
assessment. These exchanges are encouraged and will add to the overall reputation of the RC. The RC’s 
membership of the newly formed international Pharmaceutical Solid State Research Cluster will 
undoubtedly aid this process. With this additional vehicle for exchange, the RC may wish to consider the 
introduction of a requirement for a period of overseas study during the doctoral training programme, 
given the major benefits likely to result for students and the RC from such experiences. Within the 
leadership some European network or EU grant would greatly help on the international visibility and the 
further co-operations with smaller European biotech companies. 
Numeric evaluation: 4 (Excellent) 
2.5 Operational conditions 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties). 
 Identification of the RC’s strengths and challenges related to operational conditions, and the actions 
planned for their development. 
ASPECTS: Processes and good practices related to leadership and management 
 
The research infrastructure is regarded as of high quality and extensive and impressive resources are 
available to cover the most of the experimental demands of the RC’s research activities. Other specialised 
equipment is available via collaborations. RC members are involved in teaching, including provision of 
advanced courses related to research topics. 
Challenges are the continuing maintenance of research facilities and resource, and due to the turnover 
of researchers’ maintenance of know-how for existing equipment. The plan to minimise this issue by 
increasing collaboration with alumni is sound, as is the proposed hiring of a laboratory engineer by the 
Faculty of Pharmacy. 
2.6 Leadership and management in the researcher community 
 Description of  
 the execution and processes of leadership in the RC 
 how the management-related responsibilities and roles are distributed in the RC 
 how the leadership- and management-related processes support 
 high quality research 
 collaboration between principal investigators and other researchers in the RC 
 the RC’s research focus 
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 strengthening of the RC’s know-how 
 Identification of the RC’s strengths and challenges related to leadership and management, and the 
actions planned for developing the processes 
ASPECTS: Processes and good practices related to leadership and management 
 
The procedures outlined are appropriate, with the professorial PIs taking leadership and mentoring roles. 
The detailed well-functioning management team could also be used to address the identified need for 
greater inter-group and inter-Faculty collaborations, as well as providing a means to promote inter-group 
information flow. 
2.7 External competitive funding of the RC 
• The RCs were asked to provide information of such external competitive funding, where: 
• the funding decisions have been made during 1.1.2005–31.12.2010, and  
• the administrator of the funding is/has been the University of Helsinki 
• On the e-form the RCs were asked to provide: 
1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, 
TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other 
national funding organisations, other international funding organizations), and 
2) The total sum of funding which the organisation in question had decided to allocate to the RCs 
members during 1.1.2005–31.12.2010. 
Competitive funding reported in the text is also to be considered when evaluating this point. 
ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance 
 
The overall external funding approximates to €8m which indicates a high level of success with peer-
reviewed and competitive grant applications. Increased applications for EU supported activities and 
funding would help in strengthening international standing of the RC. 
2.8 The RC’s strategic action plan for 2011–2013 
• RC’s description of their future perspectives in relation to research and doctoral training. 
ASPECTS: Scientific quality, scientific significance, societal Impact, processes and good practices related to 
leadership and management, national and international collaboration, innovativeness, future significance 
 
The RC aims to build upon its current strengths of multidisciplinarity in its research focus, especially for 
preclinical formulation and mechanistic understanding of material and processing behaviour in the design 
and manufacture of solid dosage medicines. 
Additional cooperation and collaboration between the three groups in the RC is encouraged, as well as 
forging links with other RCs researching in complimentary areas of the pharmaceutical sciences (e.g. 
DePoNa, MAC). 
2.9 Evaluation of the category of the RC in the context of entity of 
the evaluation material (1-8) 
The RC’s fitness to the chosen participation category. 
Category 1. The research of the participating community represents the international cutting edge in its field. 
 
The focused research agenda of the PARTICLE RC delivered through the three groups brings forward a 
quality research output and doctoral training programme and understanding and knowledge regarding the 
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materials and processes used when preparing solid dosage medicines. The evidence for societal impact 
and innovation at the national level and international level is clear, although progress needs to be made to 
register and extend the performance at the international level. The overall assessment, and numerical 
assessment, lead to the view that the activities and performance of the RC at this stage of its development 
are more in line with participation category 2 (The research of the participating community is of high 
quality, but the community in its present composition has yet to achieve strong international recognition 
or a clear break-through), rather than the proposed participation category 1. 
Numeric evaluation: 3 (Very good) 
2.10 Short description of how the RC members contributed the 
compilation of the stage 2 material 
Satisfactory and appropriate with broad based consultation prior to final compilation of the documents. 
2.11 How the UH’s focus areas are presented in the RC’s research 
The RC has not selected a specific UH focus area under background information stage 2 documentation, 
but highlights their work in applied material science. The RC should be asked to indicate which UH focus 
group they wish to select. 
2.12 RC-specific main recommendations 
The collaborative and distinct research work of the RC, and its particular value to the Finnish community, 
is recognized and especially the quality and numerical output of the doctoral training programme. 
However the self-identified need for additional inter-group collaboration within the RC should receive the 
attention of the PIs and be resolved. 
An important aspect for the RC is to address the recommendation to increase the number of 
publications submitted to high ranking and impact journals. Achieving some success in this arena will 
provide much strength and add reputation to the RC’s current standing, especially on the international 
stage. 
The membership of the RC in the IPSSRC is seen as important, and a recommendation is for the RC to 
take a leading role in this cluster. Such investment of time and effort would bear fruit in strengthening 
collaborative opportunities and facilitate further the exchange, short term and long term, of both 
researchers and doctoral students across the EU. 
2.13 RC-specific conclusions 
The Panel were encouraged to note the strengths of the multidisciplinary research and doctoral training 
programmes undertaken by the RC. The Panel also recognized the importance of the areas of study of the 
RC in their societal contribution, especially in providing the major source of trained personnel to support 
the development sector of the pharmaceutical industry in Finland. 
A key recommendation for the RC is to focus attention on their publication strategy, and seek to secure 
more of their work being published in leading and high impact journals. Success in this area will add to the 
growing standing of the RC and help in building a stronger international reputation. 
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3 Appendices 
A. Original evaluation material 
a. Registration material – Stage 1 
b. Answers to evaluation questions – Stage 2 
c. List of publications 
d. List of other scientific activities 
B. Bibliometric analyses 
a. Analysis provided by CWTS/University of Leiden 
b. Analysis provided by Helsinki University Library (66 RCs) 
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at the University of Helsinki 2005-2010 
 
         RC-SPECIFIC MATERIAL FOR THE PEER REVIEW 
 
 
 
 
NAME OF THE RESEARCHER COMMUNITY:  
Pharmaceutical Technology and Industrial Pharmacy (PARTICLE) 
 
LEADER OF THE RESEARCHER COMMUNITY:  
Professor Jouko Yliruusi, Faculty of Pharmacy 
 
 
RC-SPECIFIC MATERIAL FOR THE PEER REVIEW: 
 Material submitted by the RC at stages 1 and 2 of the evaluation 
- STAGE 1 material: RC’s registration form (incl. list of RC participants in an excel table) 
- STAGE 2 material: RC’s answers to evaluation questions 
 TUHAT compilations of the RC members’ publications 1.1.2005-31.12.2010 
 TUHAT compilations of the RC members’ other scientific activities 1.1.2005-31.12.2010 
 Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010 
(analysis carried out by CWTS, Leiden University) 
NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing 
humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library 
(results available by the end of June, 2011) 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
 
Name: Yliruusi, Jouko 
E-mail:  
Phone: 09-19159145 
Affiliation: Faculty of Pharmacy 
Street address: Viikinkaari 5 E 
 
 
Name of the participating RC (max. 30 characters): Pharmaceutical Technology and Industrial Pharmacy 
Acronym for the participating RC (max. 10 characters): PARTICLE 
Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training 
activities) on which the RC was formed (MAX. 2200 characters with spaces): The Pharmaceutical 
Technology and Industrial Pharmacy research community (PARTICLE) forms a coherent administrative and 
research unit in the Faculty of Pharmacy, University of Helsinki. This group uses the same facilities and 
equipment and organizes common post graduate courses and seminars. We have strategically planned so 
that the research areas of three professors (PIs) in this RC (Yliruusi, Hirvonen and Juppo) are different, but 
there is some overlap and close collaboration and thesis supervision. By covering a coherent and supportive 
area of expertises we are able to give a good, versatile and up-to-date doctoral training for our PhD 
students. Prof. Yliruusi’s area of research is solid state research and pharmaceutical processes. Prof. 
Hirvonen is focusing in nanotechnologies, nanomaterials, poorly water soluble drugs and controlled release 
drug delivery systems. Prof. Juppo is responsible for a novel discipline, Industrial Pharmacy, which covers, 
e.g., pharmaceutical product development, manufacturing, marketing, whole sale trade and quality 
assurance, paediatric and veterinary drug formulations and protein drug formulations. Thus, there is a clear 
synergy between the research topics of all members, as the research of this PARTICLE RC is focussed mainly 
on solid dosage forms. It should be noted that this particular RC evaluated here, unlike most Pharmaceutics 
units in many Universities, does not include primary biopharmaceutical research focus, since in the Faculty 
of Pharmacy there is a strong Division on Biopharmaceutics and CDR research unit separately. 
 
 
Main scientific field of the RC’s research: medicine, biomedicine and healt sciences 
RC's scientific subfield 1: Pharmacology and Pharmacy 
RC's scientific subfield 2: TECHNOLOGY AND ENGINEERING 
RC's scientific subfield 3: Engineering, Manufacturing 
RC's scientific subfield 4: Materials Science, Multidisciplinary 
Other, if not in the list: Pharmaceutical Technology 
1 RESPONSIBLE PERSON 
2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC) 
3 SCIENTIFIC FIELDS OF THE RC 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
Industrial Pharmacy 
 
 
Participation category: 1. Research of the participating community represents the international cutting 
edge in its field 
Justification for the selected participation category (MAX. 2200 characters with spaces):  PARTICLE unit 
participates in category 1. Our research is highly focused in 1. Solid state materials and drug development 
processes/formulations, 2. Development of functionalized nanotechnological controlled release systems 
and their drug delivery and safety studies, and 3. Protein drug formulations research. The unit has long 
tradition of exceptionally productive doctoral education with numerous international awards for the 
supervisors and the Ph. D. graduates. During 2005–2010, the 3-4 principal investigators and 6-8 senior 
researchers and post-docs at a time produced more than 100 peer reviewed original research articles and 
22 Ph. D. theses (more than 1/3 of the six disciplines in the Faculty). Two theses (J. Aaltonen, S. Mirza) were 
awarded international AAPS Awards and one (S. Hirsjärvi) national Albert Wuokko Prize as the best theses 
in pharmaceutical sciences that year. Professor J. Yliruusi received also the prestigious Albert Wuokko 
Award for his solid state drug research and excellent researcher education (2009), while Prof. J. Hirvonen 
was awarded the CRS/Eurand Grand Prize in 2007 (Novel Approaches in Oral Drug Delivery), post-doc T. 
Laaksonen the national Komppa Prize for the best thesis in Chemistry (2008), and post-doc H. Santos the 
Talent Award in Science by the Portuguese Government, Ministry of Foreigner Affairs (2010). A. Juppo from 
AstraZeneca was nominated as the first Professor of Industrial Pharmacy in 2006, which further 
strengthened the collaboration with pharmaceutical industry. Of the former PARTICLE members, 7 
professors were nominated during the evaluation period (J. Rantanen in Copenhagen, N. Sandler in Åbo 
Akademi, J. Heinämäki in Tartu, H. Guo in Shangdon, H.A. Rashid in Bangladesh, Meike Römer in Münster 
and M. Cerveza in Habana). Collegial and collaborative leadership and management practices in PARTICLE, 
together with challenging yet encouraging examples of the unit leaders and senior members, have created 
an excellent atmosphere and motivation for self-development of the younger scientists for academic drug 
research and research-based education, with excellent prospects for the future careers also in national and 
internationa 
 
 
Public description of the RC's research and doctoral training (MAX. 2200 characters with spaces): The goal 
of the oral solid state drug research oriented PARTICLE RC and the researchers involved is to promote 
scientific excellence in the fields of drug formulations and applied materials sciences. To accomplish this, 
the unit will identify and promote multidisciplinary research on essential areas in pharmaceutical 
technology and industrial pharmacy: Development of novel drug delivery systems, drug formulation 
studies, pharmaceutical materials research, physical process research and selected research topics in 
industrial pharmacy. 
 
The research in the PARTICLE RC has been organised in few smaller research groups. Oral drug delivery 
route (the most common way to administer drugs) is the main focus area in the drug delivery systems and 
formulations. The solid state research project topics range from crystallization, polymorph screening, 
4 RC'S PARTICIPATION CATEGORY 
5 DESCRIPTION OF THE RC'S RESEARCH AND DOCTORAL TRAINING 
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INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
particle formation, process induced transformations, process analytical technologies (PAT), 
nanotechnological materials and drug formulations, protein pharmaceuticals, and veterinary and paediatric 
formulations. 
The main training objectives of the RC are:  
-to educate a top-level specialists within the field of selected research topics  
-to motivate young researchers in the present fields of research by promoting the mobility and 
internationalisation  
-to give possibilities to cross-utilize advanced methodologies and equipment in the laboratories of partner 
institutions  
-to acquire skills and ability to build up new competitive research and training also in the future. 
 
By careful design of research projects, and complementary career development plans, the young 
researchers will acquire multidisciplinary and interdisciplinary skills, yet approaching increased 
independence during the process towards the thesis and post doctoral training. 
 
The PARTICLE RC believes in the training-through-research combined with high level ethics, social and 
management skills. Mainly these are taught and learned by setting examples, in every-day practical 
research and communication. 
Significance of the RC's research and doctoral training for the University of Helsinki (MAX. 2200 
characters with spaces): PARTICLE RC doctoral productivity has been very high for years. Still we have been 
able to keep up good and often excellent scientific level. The well organized and effective doctoral training 
produces continuously better researchers and better teachers for the University. The societal impact of our 
research is mostly due to the research results which can easily be adapted to the benefit of pharmaceutical 
academic and industry research. Many research projects are done in collaboration with the pharmaceutical 
industry. 
 
Integration of research and teaching is essential part of our training program. In every day teaching practice 
it is important that knowledge is quickly transferred also for undergraduate level students.  
 
So far all our finalised Ph.D. students (totally 22 during the evaluation period) have received permanent 
positions or are continuing their research as post doctoral researchers. PARTICLE RC is multinational and we 
have lot of connections to various materials science and other groups world-widely. This keeps our research 
items up-to-date and also supports students visits abroad. 
 
During the evaluation period the RC has been able to get a lot of external funding. Practically all research 
and in some years also about 50% of teaching hours have been paid by external funding. 
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The RC believes in the training-through-research combined with high level ethics, social and management 
skills. In practice, ethical issues and social and management skills are mainly taught and learned by setting 
examples, in every-day practical research and communication. In successful research training one of the 
most important issue is real commitment of both teachers and students. When a young researchers starts 
as a new member in our RC, he/she in practice invests his/her whole life – in return the RC honestly takes 
care of the new-comer by all measures in its power. 
Keywords: pharmaceutical technology, industrial pharmacy, drug, drug product, formulation, drug delivery 
system, materials research, crystallization, polymorph screening, particle design, process induced 
transformations, nanotechnology, nanomaterials, PAT, protein pharmaceuticals, veterinary formulations, 
paediatric formulations. 
 
 
Justified estimate of the quality of the RC's research and doctoral training at national and international 
level during 2005-2010 (MAX. 2200 characters with spaces): Number of original publications during the 
evaluation period is over 100. Majority of the publications are published in high impact peer-reviewed 
journals. 
 
Totally seven of our earlier students and researchers have obtained Professorship outside the University of 
Helsinki (Jukka Rantanen, Denmark/Copenhagen; Jyrki Heinämäki, Estonia/Tartu; Niklas Sandler, 
Finland/Åbo Akademi; Hongxia Guo, Shandong/China; Harun Rashid Ar, Northern University/Bangladesh; 
Meike Römer, Munster/Germany; Mirna Cervera Havana/Cuba) 
 
Many of our post doctoral researchers have spent one or more years abroad at various high level research 
teams. For example, currently Ph.D. Mirza Sabiruddin is on his post-doctoral year at Harvard 
University/USA, Ph.D. Samuli Hirsjärvi at University of Angers/France and Ph.D. Sanna Siissalo at Groningen 
University/Netherlands. At the end of this year, Ph.D. Inna Miroshnyk, is starting her post doctoral year at 
Massachusetts Institute of Technology/USA. 
 
During the years, four of our students Ph.D. Theses have been awarded by the American Association of 
Pharmaceutical Sciences Outstanding Graduate Student Research Award (Jukka Rantanen, Niklas Sandler, 
Jaakko Aaltonen, Sabiruddin Mirza). In 2008 Samuli Hirsjärvi obtained Albert Wuokko Award of his 
distinguished doctoral thesis. In 2010 professor Yliruusi obtained Albert Wuokko award especially on his 
contribution to improve the quality of postgraduate studies and Ph.D. Theses made in Finland. 
 
In Europe there are currently numerous small bio- and drug companies, which are mainly focusing in the 
high-risk drug discovery research. It is foreseen, that there is also an increasing need for drug formulation 
and manufacturing research. That's why  the Faculty of Pharmacy has taken the step towards Industrial 
Pharmacy research and teaching within the Division of Pharmaceutical Technology (PARTICLE). 
6 QUALITY OF RC'S RESEARCH AND DOCTORAL TRAINING 
 
 
5 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC STAGE 1 MATERIAL (registration form) 
 
 
 
Finnish Higher Education Evaluation Council (FINHEEC) has designated the Faculty of Pharmacy, UH as one 
of the ten National Centres of Excellence in University Education units for 2010-2012.  Earlier the Faculty of 
Pharmacy  has obtained University's Teaching Quality awards in 2007-2009 and also in 2005. 
Comments on how the RC's scientific productivity and doctoral training should be evaluated (MAX. 2200 
characters with spaces): We suggest that the next methods (and or criteria) could be used: 
 
1. Comparison RC's scientific productivity 
- Number of peer-reviewed publications 
- Number of peer-reviewed publications per person in the RC 
- Amount of money needed on average for one peer-reviewed publication 
- Amount of money needed on average for one PhD 
- Governmental (University) money per person in the RC on average 
- External funding per person in the RC on average 
 
2. Assessing of the RC's doctoral training 
- Number of Ph.D. studies completed during the evaluation period 
- Average age of new doctors 
- Average time in months needed to obtain the doctoral degree 
- Gender balance 
- Number of foreign students in the RC's environment 
- Ph.D. Theses awards obtained 
- Employment in Academia and industry 
 
3. Publishing strategy 
The RC has its own written publishing strategy. We have listed Scientific Journals in two main categories. 
The idea is that the publications will be published in the highest category journals. 
Category 1: The most preferable journals in Pharmaceutical Technology and Industrial Pharmacy. This 
group also includes special scientific journals as Nature and Science. The target is to publish in this category 
journals. 
Category 2: Good, acceptable journals in Pharmaceutical Technology and Industrial Pharmacy. These 
journals can be used, but they are not actually suggested. 
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In addition, there is a third (not precisely determined) category, which includes other good journals, which 
however, are not representing our own main research fields. These journals may be, for example, focused 
in chemical, physical, colloidal and surface sciences, polymer sciences, and food sciences. 
 
4. Benchmarking and comparison with similar type units within Europe: Comparable with the similar high-
class Pharmaceutical Technology oriented units in Europe: University of Ghent, Belgium and University of 
Heinrich Heine, Düsseldorf, Germany. 
LIST OF RC MEMBERS
NAME OF THE RESEARCHER COMMUNITY: PHARMACEUTICAL TECHNOLOGY AND INDUSTRIAL PHARMACY (PARTICLE)
RC-LEADER J. Yliruusi
CATEGORY 1
Last name First name
PI-status 
(TUHAT, 
29.11.2010)
Title of research and 
teaching personnel Affiliation 
1 Airaksinen Sari University Lecturer Faculty of Pharmacy
2 Almeida Santos Helder Postdoctoral Researcher Faculty of Pharmacy
3 Antikainen Osmo University Lecturer Faculty of Pharmacy
4 Christiansen Leena University Lecturer Faculty of Pharmacy
5 Heinämäki Jyrki x University Lecturer Faculty of Pharmacy
6 Hirvonen Jouni x Professor Faculty of Pharmacy
7 Juppo Anne x Professor Faculty of Pharmacy
8 Kaukonen Ann-Marie Senior Researcher Faculty of Pharmacy
9 Kivikero Niina Postdoctoral Researcher Faculty of Pharmacy
10 Laaksonen Timo Postdoctoral Researcher Faculty of Pharmacy
11 Lakio Satu Postdoctoral Researcher Faculty of Pharmacy
12 Mirza Sabirrudin Postdoctoral Researcher Faculty of Pharmacy
13 Peltonen Leena University Lecturer Faculty of Pharmacy
14 Rantanen Jukka Senior Researcher Faculty of Pharmacy
15 Sandler Niklas Professor Faculty of Pharmacy
16 Sivén Mia University Lecturer Faculty of Pharmacy
17 Strachan Clare University Researcher Faculty of Pharmacy
18 Yliruusi Jouko x Professor Faculty of Pharmacy
19 Aaltonen Jaakko Doctor Faculty of Pharmacy
20 Heikkilä Tiina Doctor Faculty of Pharmacy
21 Hirsjärvi Samuli Doctor Faculty of Pharmacy
22 Hoppu Pekka Doctor Faculty of Pharmacy
23 Miroshnyk Inna Doctor Faculty of Pharmacy
24 Römer Meike Doctor Faculty of Pharmacy
25 Savolainen Marja Doctor Faculty of Pharmacy
26 Siissalo Sanna Doctor Faculty of Pharmacy
27 Vihola Henna Doctor Faculty of Pharmacy
28 Bimbo Luis Doctoral candidate Faculty of Pharmacy
29 Ehlers Henrik Doctoral candidate Faculty of Pharmacy
30 Genina Natalia Doctoral candidate Faculty of Pharmacy
31 Halenius Anna Doctoral candidate Faculty of Pharmacy
32 Hautala Jaana Doctoral candidate Faculty of Pharmacy
33 Heljo Petteri Doctoral candidate Faculty of Pharmacy
34 Kolakovic Ruzica Doctoral candidate Faculty of Pharmacy
35 Limnell Tarja Doctoral candidate Faculty of Pharmacy
36 Liu Peng Doctoral candidate Faculty of Pharmacy
37 Raiman Johanna Doctoral candidate Faculty of Pharmacy
38 Rosenqvist Kirsi Doctoral candidate Faculty of Pharmacy
39 Shevcenko Anna Doctoral candidate Faculty of Pharmacy
40 Siiriä Simo Doctoral candidate Faculty of Pharmacy
41 Soikkeli Anne Doctoral candidate Faculty of Pharmacy
42 Soppela Ira Doctoral candidate Faculty of Pharmacy
43 Tahvanainen Maria Doctoral candidate Faculty of Pharmacy
44 Valo Hanna Doctoral candidate Faculty of Pharmacy
45 Ylinärä Hilkka Doctoral candidate Faculty of Pharmacy
Industrial pharmacy (licentiate thesis)
Gartman Minna Licentiate candidate
Gummerus Anu Licentiate candidate
Harjuketo Eija Licentiate candidate
Hiltunen Mikko Licentiate candidate
Hiltunen Tommi Licentiate candidate
Holm Tiina Licentiate candidate
Kujala Satu Licentiate candidate
Taipale Krista Licentiate candidate
Torkko Marianne Licentiate candidate
Linna Anu Licentiate candidate
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Name of the RC’s responsible person: Yliruusi, Jouko 
E-mail of the RC’s responsible person:   
Name and acronym of the participating RC: PHARMACEUTICAL TECHNOLOGY AND INDUSTRIAL 
PHARMACY, PARTICLE 
The RC’s research represents the following key focus area of UH: -- Select -- 
Comments for selecting/not selecting the key focus area: The goal of the RC is to promote scientific 
excellence in the fields of applied materials sciences. To accomplish this, the RC promotes multidisciplinary 
research on essential areas in pharmaceutical technology and industrial pharmacy. 
 
Key research questions are related to all phenomena that occur in drugs during processing and phenomena 
that determine drugs' properties and physical and chemical stability and performance. 
 
 
 Description of the RC’s research focus, the quality of the RC’s research (incl. key research 
questions and results) and the scientific significance of the RC’s research for the research 
field(s).  
The Pharmaceutical Technology and Industrial Pharmacy research community (PARTICLE) forms a 
coherent administrative and research unit in the Faculty of Pharmacy, University of Helsinki. This group 
uses the same facilities and equipment and organizes common postgraduate courses and seminars. We 
have strategically planned that the research areas of the three professors (PIs) in this RC (Yliruusi, 
Hirvonen and Juppo) are different, but with some overlap to enable close collaboration and thesis co-
supervision. By covering supportive areas of expertise we are able to give a good, versatile and up-to-
date doctoral training for our Ph.D. students. There is a clear synergy between the research topics of all 
members, as the research of this PARTICLE RC is focussed mainly on solid dosage forms. Our research is 
at the moment highly focused in 1. Solid state materials and drug development processes and 
formulations and 2. Development of functionalized nanotechnological controlled release systems and 
their drug delivery and safety studies. 
 
Key research questions are related to the fundamental approach that all relevant phenomena that occur 
in drugs during processing and phenomena that determine drug products’ mechanical properties and 
physical and chemical stability should be explained and understood at the molecular level. This is what 
the RC means with "Molecular based pharmaceutical technology". In most of our research it is also 
essential to know how to exploit experimental design and data analysis techniques in studying 
multivariate pharmaceutical formulation and processing systems. 
 
Key past and on-going research questions are e.g.: 
1) How ideal drug crystals, cocrystals and polymorphic forms are formed, what are the mechanisms that 
stabilize amorphous drugs and how to process amorphous drugs with low glass transition temperature. 
The processing technology has been patented. These findings are utilized in formulation of poorly 
soluble drugs in solid dispersions, nanocrystals or therapeutical proteins in freeze-dried and spray-dried 
formulations.  
 
BACKGROUND INFORMATION 
1 FOCUS AND QUALITY OF RC'S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES) 
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2) Mixed crystal design based on integration of molecular modeling and laboratory work. To date few 
new mixed crystals of active APIs have been developed. 
 
3) Powder technology: New in-line methods to determine granule size during granulation, and a totally 
new technique to determine flow properties of cohesive powders have been designed. No other 
research group has succeeded in this. These technologies have been patented. 
 
4) Particle and surface engineering research to control particle size and morphology in a wide range. 
This enables better drug material processability and general functionality. 
 
5) Novel film coating techniques and development of new coating materials and formulations. Stable 
films have been developed from cellulose derivatives, chitosan, chitin, modified whey proteins, zein and 
native starches. 
 
6) Poorly soluble drugs: Successful improvements of dissolution rate by nanosizing or by entrapping the 
drug compounds into mesoporous silicon and silica structures have been done for many different drugs 
and drug formulations. 
 
7) Toxicity of novel biocompatible nanomaterials: We have shown that mesoporous silicon particles and 
surface-modified nanomaterials can be safely used in pharmaceutical applications and have studied 
their biodistributions. 
 
8) Enabling pharmaceutical formulations of nanomaterials: We have studied and prepared formulations 
of such diverse materials as mesoporous silicon, nanofibrillar cellulose and amphiphilic proteins in the 
context of tabletting and/or controlled release of poorly soluble compounds. 
 
9) Method development on drug dissolution and solubility determinations with high-throughput 
screening methods. 
 
During 2005–2010, the 3-4 principal investigators and 6-8 senior researchers and post-docs of the RC 
produced more than 100 peer-reviewed original research articles. Most of these have been published in 
high impact peer-reviewed journals. Publication media varies from general pharmaceutical journals (e.g. 
Int.J.Pharm, Eur.J.Pharm.Sci., J. Control. Release) to specialized journals in adjacent fields such as 
nanotechnology (e.g. Small, ACS Nano), chemistry and materials science (e.g. Biomaterials). More than 
10 of the publications have been published in journals with impact factor > 5, signifying the overall 
quality of the publications. 
 
The unit has a long tradition of exceptionally productive doctoral education with numerous international 
awards for the supervisors and the Ph. D. graduates. During the evaluation period, 22 Ph.D. theses were 
completed in the RC (more than 1/3 of the six disciplines in the Faculty). Two theses (Jaakko Aaltonen, 
Sabiruddin Mirza) were awarded international AAPS Awards and one (Samuli Hirsjärvi) national Albert 
Wuokko Prize as the best theses in pharmaceutical sciences that year. Professor J. Yliruusi received also 
the prestigious Albert Wuokko Award for his solid state drug research and excellent researcher 
education (2009), while Prof. J. Hirvonen was awarded the CRS/Eurand Grand Prize in 2007 (Novel 
Approaches in Oral Drug Delivery), post-doc Timo Laaksonen the national Komppa Prize for the best 
doctoral thesis in Chemistry (2008), and post-doc Helder Santos the Talent Award in Science by the 
Portuguese Government, Ministry of Foreigner Affairs (2010). Of the former PARTICLE members, six 
have obtained Professorships outside the University of Helsinki (Jukka Rantanen, Denmark/Copenhagen; 
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Jyrki Heinämäki, Estonia/Tartu; Niklas Sandler, Finland/Åbo Akademi; Hongxia Guo, Shandong/China; 
Harun Rashid Ar, Northern University/Bangladesh; Mirna Cervera Havana/Cuba). 
 
In addition to the research awards, Finnish Higher Education Evaluation Council (FINHEEC) has 
designated the Faculty of Pharmacy as one of the ten National Centres of Excellence in University 
Education for 2010-2012. Earlier the Faculty of Pharmacy has obtained University's Teaching Quality 
awards in 2007-2009 and also in 2005. 
 Ways to strengthen the focus and improve the quality of the RC’s research. 
International collaboration with the top universities should be further increased. More participation in 
EU consortia should be encouraged and reached in addition to the LIINTOP (Liver Intestine Optimisation) 
FP6 research consortium in 2007-2010. The PSSRC cluster (www.pssrc.org) offers a great opportunity to 
utilise the equipment and knowledge of several top universities. 
 
The criteria of the appropriate peer-reviewed journals could be tightened even further. The RC should 
perhaps also adopt more challenging and risky research topics, produce publications (in collaboration 
with multidisciplinary research partners) with even wider application potential after careful 
identification of current hot topics in the field.  
 
In graduate education, research-based learning and a research-focused study path for selected top 
students including practice periods in research projects during the studies would improve the starting 
level of future Ph.D. students and further improve the quality of the research. 
 
 
  How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and 
selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, 
departments/institutes, and potential graduate schools/doctoral programmes, good practises and 
quality assurance in doctoral training, and assuring good career perspectives for the doctoral 
candidates/fresh doctorates.  
The multidisciplinary nature of RC’s research means that students in RC have variable backgrounds. 
Ph.D. students have masters e.g. in pharmacy, physics, chemistry or biotechnology. 
 
The recruitment is based on individual assessments of the students. Personal experience of working 
with the new doctoral candidates is highly valued before making recruitment decisions. The intake of 
new students has been quite stable on the long run, averaging at approx. 5/year. 
 
International candidates are very welcome to join the RC, both at M.Sc. and Ph.D. student level. Foreign 
students are mainly from European countries, but also from China, Russia, and Bangladesh. Approx. 25% 
of the RC’s Ph.D. students (between 2005-2010) are from abroad. 
 
Each Ph.D. student has a professor as the main supervisor and one or two post-doctoral supervisors, 
who are working closely with the students on their Ph.D. thesis and laboratory work. During Ph.D. 
studies, most of the students also work at least some time in externally funded projects that have their 
own steering groups and regular meetings. These meetings are used to set goals for the students and to 
track their progress. 
 
The progress of the Ph.D. students is monitored by each supervisor, and officially in their mandatory 
research plan defense, which takes place at mid-point of the Ph.D. thesis project. In the defense, the 
2 PRACTISES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES) 
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student presents the results from the first half of the thesis project (usually 2 articles) and outlines the 
plan to finalize the thesis. The defense is evaluated by three external referees. 
 
Through regular meetings and evaluations, an open interaction between the supervisors and doctoral 
candidates is encouraged. The hierarchy of the RC is very low, and students can easily get help from all 
RC members. 
 
RC has extensive collaboration inside the University of Helsinki and with groups from other 
Finnish/International Universities/Institutions, as well as with national/international industrial and other 
non-academic partners (several private companies, hospitals), mainly within the EU, but also in the USA, 
New Zealand, India, Japan and China. The collaborations include many multidisciplinary fields of 
research, e.g., pharmacy, physics, engineering, medicine, chemistry, biotechnology and food technology. 
Most of the M.Sc. and Ph.D. degrees taken in our RC are a result of joint doctoral training and research 
activities, involving these collaborations.  
 
Our RC has participated as a member or as a main coordinator in several national/international research 
projects and networks. These projects have been funded mainly by the Finnish Funding Agency for 
Technology and Innovation (TEKES), Academy of Finland, European Union and domestic/international 
drug industry.  
 
The RC has had numerous joint research and doctoral training projects within the University of Helsinki 
(including the Centre for Drug Research, CDR) and with many national universities and private research 
organizations in Finland. The RC is involved in the national Graduate School in Pharmaceutical Research 
and National Doctoral Programme in Nanoscience.  
 
On the international level, the RC has established research collaboration with an extensive number of 
academic units and private sector companies. This cooperation has supported numerous Ph.D. theses 
and resulted in several appointments of our earlier Ph.D. students as professors.  
 
Collaboration is also promoted through National Graduate School networks with travel grants. 
International collaboration is also promoted through former RC members appointed as Professors or 
University Lecturers in Universities/Institutions both in Finland and abroad. External collaboration is 
supported by the supervisors from the very beginning of the Ph.D. studies, e.g., through participation in 
several international scientific conferences every year and encouraging people to spend time abroad in 
different laboratories. 
 
The RC is a founding member of Pharmaceutical Solid State Research Cluster (PSSRC), which is 
composed of eight academic research centers in the pharmaceutical sciences all over the world 
(http://www.pssrc.org). The PSSRC network gives a possibility to send Ph.D. students to the member 
Universities for utilization of equipment and for collaborative projects, and PSSRC annual symposium 
gives good forum for Ph.D. students to present their results. 
 
Most Ph.D. students in the Faculty of Pharmacy are members of the national Graduate School in 
Pharmaceutical Research, and have to submit a research plan before initiating the doctoral training. 
Doctoral training complies with the Graduate School instructions. A compulsory preliminary exam 
ensures sufficient scientific knowledge and a compulsory defense of the research plan ensures that the 
student has sufficient theoretical knowledge, adequate insight into the quality of the research, and gives 
the tools and recommendations by the evaluation board needed for successful completion of the 
degree. 
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All Ph.D students are members of (at least) one research group. The aim is to involve the students in 
external projects. This gives insights into the fundamentals of scientific work and scientific project 
management, preparing them also for the more independent post-doctoral research. The projects are 
driven by schedules, requiring systematic research according to research plans. Quality of Ph.D. 
students’ own research plans are reviewed by independent reviewers. Assigned grants and external 
projects can also be seen as quality descriptors of the achieved results as well as merits supporting 
future applications. 
 
The quality of the doctoral research is monitored by the supervisors and co-authors. All students are 
met as individuals. The quality of the work is reviewed and instructions for improvements are given in 
annual development discussions with the RC’s principal investigators. The theses are article-based with 
an emphasis on articles published in international high-quality peer-reviewed journals determined by a 
list of the most preferred publication journals identified for the RC. 
 
The RC has weekly divisional research seminars held by M.Sc./Ph.D. students or Postdocs/PIs. In 
addition, there are regular group meetings in which the research of the doctoral candidates is discussed 
regularly. The RC has biannual Divisional development days, in which the status of the studies of all 
doctoral candidates is presented, and other research-related relevant issues are discussed. The goal is to 
have a public follow-up of the studies and to encourage the students to complete their studies. RC’s 
Professors also have one-day planning meetings four times a year. 
 
The RC is participating actively and responsibly for the annual events and meetings of the Finnish Society 
of Physical Pharmacy. The Society is driven by the doctoral candidates representing both academia and 
industry.  
 
During the past five years all researchers of the RC have been fully employed after obtaining their Ph.D. 
degree. University career opportunities include post-doctoral years abroad, special scientists’ posts and 
professorships, working in industry and in national regulatory authorities (FIMEA). In total six former RC 
members have obtained Professorships and almost all Ph.D.s have spent a post-doctoral period abroad. 
 RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions 
planned for their development. 
Strengths 
• Efficacy of doctoral training: 22 high-level Ph.D. degrees obtained in 2005-2010 
• Awards for excellent doctoral theses (2 AAPS awards, 1 Albert Wuokko award) 
• Research plan defense 
• Good supervision system, low number of Ph.D. drop-outs  
• International doctoral candidates 
 
Challenges 
• Clear quality indicators are not listed 
• Cross-interaction between the Ph.D. students inside the RC is too limited 
• The RC has no joint doctoral training programs 
• Too limited participation in EU projects 
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Action plans 
Important fields in the doctoral training to be developed are: 
• Arrange a standard 6-month training period abroad for the RC's Ph.D. students  
• More EU funding needed, e.g. Marie Curie funding, to improve doctoral training, organise joint courses 
and increase mobility 
• Industrial pharmacy licentiate students will be incorporated more tightly into the RC 
• Ph.D. and M.Sc. student seminars will be developed further. 
 
 
 Description of how the RC interacts with and contributes to the society (collaboration with public, 
private and/or 3rd sector).  
The research of RC PARTICLE is closely related to drug development, formulation and manufacturing. 
Therefore the societal impact is closely related to these topics. Most of our societal impact comes 
through industrial collaboration and student (M.Sc., Ph.D.) education. We have had several short- or 
long-term industrial research projects assisting pharmaceutical material research and product 
development. These industrial collaborations guarantee that our research is relevant and highly 
interesting for the pharmaceutical industry. These projects have resulted in numerous publications and 
theses. So far all our finalised Ph.D. students (22 during the evaluation period) have received permanent 
positions. Many of them are continuing their research at post-doctoral or even professor level. The RC 
has collaborated with the public sector, for example by assisting the Helsinki University Hospital in 
development of paediatric formulations. We believe that it is ethically important to give help in these 
areas. Prof. Yliruusi has also acted as a scientific expert on pharmaceutical patent conflict trials. 
 
Currently, there are numerous small bio- and drug development companies in Europe, which are mainly 
focusing in high-risk drug discovery research. It is foreseen, that ever more drug formulation and 
manufacturing research is needed. To strengthen Finnish drug development knowledge, the Faculty of 
Pharmacy has started Industrial Pharmacy research and teaching (Prof. Juppo). These specialized studies 
are meant for persons with B.Sc. or M.Sc. in pharmacy and working in the pharmaceutical industry. 
 
Since we believe that it is important to spread the knowledge obtained in the research projects, the RC 
members have given several popular oral presentations and lectures for professional and non-
professional audiences in general open education, together with professional seminars and meetings 
and alumni get-togethers. The RC members have also been interviewed for the newspapers, 
professional magazines and for TV. 
 
RC members have participated in several different expert groups for health care politics, industrial 
project development, pharmaceutical continuous education, doctoral training development, and in 
national and international planning committees e.g. for specialized studies in pharmacy and education 
in veterinary formulations. Prof. Hirvonen is a member of EDQM drug formulations section to develop 
the European Pharmacopoeia on these subjects. The principal investigators in the group have also 
evaluated grant proposals (FWO-Vlaanderen, Belgium, EAS-Enterprise Estonia) and given input for the 
forthcoming EU calls (IMI, Innovative Medicines Initiatives). 
 
 
3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES) 
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 Ways to strengthen the societal impact of the RC’s research and doctoral training. 
Industrial collaborations are crucial for the RC also in the future. Not only because of research funding, 
but also to keep on the track of front-line research topics that are truly beneficial to the pharmaceutical 
industry. The RC should be better in proactive planning of collaborations and forming strategic 
partnerships. 
 
The doctoral and licentiate training is currently well connected with the pharmaceutical industry. 
However, the collaboration with former students (alumni) could be utilised better since they form an 
excellent network and a group of “critical friends” in the private sector. 
 
In the future, the ethical aspects of research will have an even more important status, e.g. 
environmental aspects of drug manufacturing and packaging, development of drugs for the developing 
countries, and development of paediatric and geriatric formulations. These should be carefully 
evaluated and, when feasible, taken into account in the RC’s research and education strategies. 
 
 
 
 Description of the RC’s research collaborations and joint doctoral training activities and how the RC 
has promoted researcher mobility.  
The RC has an extensive national and international collaboration in research and doctoral training: 
several research groups at the University of Helsinki, research groups form other universities and 
research institutions worldwide, and national and international industrial partners ranging from small 
local to large global companies. The multidisciplinary collaboration projects cover the fields of, e.g., 
pharmaceutical sciences, physics, engineering, medicine, and chemistry. Research projects are typically 
funded by various funding elements including TEKES (the Finnish Funding Agency for Technology and 
Innovation), Academy of Finland, European Union (EU) and industrial funding from domestic and 
international private companies.  
 
The total number of students and researchers participated in international exchange programmes in 
2007-2010 were 54 and 13, respectively. RC has attracted many undergraduate and postgraduate 
students, and researchers from all over the world (EU, Russia, China, Cuba, Bangladesh, Chile, New 
Zealand). Over 40 international M.Sc. and Ph.D. students or postdoctoral researchers visited the RC 
during 2005-2010. The number of long-term visits (over 12 months) was 6. Five Ph.D. students from 
abroad obtained their Ph.D. degrees between 2005 and 2010. The RC has also participated in the 
supervision of two Ph.D. students that obtained their Ph.D. degrees abroad. A total number of short-
term visits (less than 12 months) was 29 in 2005-2010. Research visits abroad during 2005-2010 include 
7 long-term visits, most of which were post-doctoral research periods.  
 
The skilled staff and modern infrastructure enable high-quality training and research visits for 
international researchers. International collaboration has also been promoted by a substantial number 
of RC alumni currently located at other universities/institutions. RC is an active (charter) member in the 
international Pharmaceutical Solid State Research Cluster (PSSRC). The aim of PSSRC is to initiate and 
foster academic and industrial research collaboration between its members in the field of solid-state 
pharmaceutics, provide a discussion forum, and exchange members of the cluster through student and 
staff research visits. Staff recruitment policy of the RC embraces people from different countries. 
 
4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER 
MOBILITY (MAX. 4400 CHARACTERS WITH SPACES) 
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RC’s own Ph.D. students are encouraged to make short-term research visits (3–12 months) to partner 
laboratories. The aims of these visits are joint publications, to widen the students’ scientific perspectives 
and strengthen the basis of research collaboration. Researchers are also encouraged and supported to 
attend scientific meetings since the very beginning of the Ph.D. studies. In addition, the RC has 
promoted researcher mobility by maintaining the existing networks, increasing the research interactions 
within the networks, and using them to find new interesting collaboration partners.  
 
The research collaboration and researcher mobility can be developed in the future by participating more 
in the EU Marie Curie ITN and/or RTN projects making new transnational collaboration initiatives, 
developing web-based visibility and information of the RC. 
 RC’s strengths and challenges related to research collaboration and researcher mobility, and the 
actions planned for their development. 
Strengths: 
• PSSRC membership enables ‘an open invitation’ to any Cluster centre 
• Vast number of international and national contacts  
• RC encourages Ph.D. students to establish their own networks 
• RC has a good reputation abroad and research facilities are excellent  
• RC is highly multidisciplinary and multicultural 
 
Challenges: 
• More joint research within the RC needs to be developed.  
• To motivate the RC members to participate even more actively in international mobility  
• Difficulties to create research positions for incoming/returning researchers   
 
Actions for further development 
Building partnerships is increasingly important. Funding applications through national and international 
funding institutions should allocate more funds for researcher mobility. Overall, new ways are needed in 
order to allow the researchers to visit abroad faster and with minimum bureaucratic load. 
 
 
 Description of the operational conditions in the RC’s research environment (e.g. research 
infrastructure, balance between research and teaching duties).  
RC´s research infrastructure at the Division of Pharmaceutical Technology is of high international quality. 
The Division has a broad range of essential preparative and analytical equipment suited for RC´s focused 
research activities in solid dosage forms. 
 
The RC has versatile equipment from molecule crystallization to final dosage form processing (from 
miniature to lab-scale and pilot-scale). Formulation techniques for traditional (e.g. granulation, 
tabletting, coating, freeze-drying) as well as newer (e.g. proteins, nanoparticulate and transdermal) drug 
delivery systems are available. RC has an extensive array of advanced tools for physical and chemical 
analysis (HTS and larger scale). RC has also several (commercialized) in-house techniques for physical 
characterization of pharmaceutical solids and process analytical technologies (PAT). RC has facilities and 
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expertise also for cellular toxicity and permeability studies including aseptic laboratories for cell 
culturing and cell monolayer preparations, toxicity assays and permeability testing platforms. The RC’s 
research topics also require specialized equipment not feasible or financially possible to own by the RC 
itself, but these are all achievable through existing collaborations.  
 
RC members are involved in teaching on several courses. Most of the advanced courses are directly 
related to the RC’s research topics and require that the teacher is also actively involved in research and 
has up-to-date knowledge of the field. All RC members participate in teaching. Externally funded 
employees are sometimes limited in their teaching responsibilities by the rules given by the funding 
source. Balancing these issues is a continuing challenge for the RC and educational development 
towards research-based courses. 
 RC’s strengths and challenges related to operational conditions, and the actions planned for their 
development. 
A major strength of the RC is the high-level infrastructure at its disposal, both in-house and through the 
high-level national and international collaborations. Also researchers in the RC with wide variety of 
backgrounds (e.g. pharmaceutics, physical chemistry, engineering, physics, biochemistry) increase the 
in-house possibilities for efficient utilization of the existing research methodologies and the novel 
process and analytical techniques. 
 
A future challenge and concern related to the operational conditions is the maintenance of the research 
infrastructure. The importance of fruitful collaboration will further increase. Faculty of Pharmacy will 
hire a new laboratory engineer in 2011. 
 
Another challenge is the turnover of researchers and, related to that, maintenance of the know-how for 
the existing equipment and laboratory facilities in the RC. By continuing the co-working with the alumni 
afterwards, this is a possibility to further increase the collaborative actions. Also the role of in-house 
training and mentoring should be further emphasized in the RC. 
 
 
 
 Description of the execution and processes of leadership in the RC, how the management-related 
responsibilities and roles are distributed in the RC and how the leadership- and management-related 
processes support high quality research, collaboration between principal investigators and other 
researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.  
The RC is a Division within the Faculty of Pharmacy with disciplines of pharmaceutical technology and 
industrial pharmacy. We have monthly division meetings where administration, infrastructure, teaching, 
research, visitor and ex-patriate and safety issues are handled. This meeting is chaired by a University 
Lecturer and the whole staff participates. Also 1-2 Division days are organized outside the University for 
development of specific topics. The agenda of these are planned and chaired by the Professors, but 
initiatives come from all RC members and staff. Three Professors of the Division have strategic one-day 
meetings 5-6 times per year, where the strategic issues, future development and common topics are 
discussed. Senior scientist meetings (Professors and University Lecturers) are monthly meetings to 
discuss research, administrative and teaching issues. University Lecturers have also their own meetings 
to discuss the laboratory facilities 3 times/year. The laboratory facility responsibilities are divided 
amongst the University Lecturers and the meeting is chaired by one of the Lecturers. Two of the RCs 
research groups (Prof. Hirvonen and Prof. Juppo) have regular group meetings every month where the 
focus is on research projects and scientific results. The third group (Prof. Yliruusi) does not have joint 
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group meetings, but managing is more personal in minor groups according to the various projects and 
topics. For confidentiality reasons due to industrial collaborations, these discussions are limited to 
smaller groups and project teams. However, there is a weekly seminar where all the RC members, Ph.D. 
students and M.Sc. students are giving scientific presentations on their results. This seminar series is 
chaired by a post-doctoral researcher. The Ph.D. students have also regular meetings with their 
supervisors, approximately every second week and ad-hoc when requested. Prof. Yliruusi is the Head of 
the Division having the administrative responsibility of the Division including the personnel, facilities and 
budget. The quality, health and safety group has meetings 4-5 times/year. This group is chaired by the 
Head of the Division and it performs internal inspections 1-2 times/year. Once a year the RC has a 
cleaning day organized by the University Lecturers and the whole staff participates. All these regular 
meetings and activities guarantee, we believe, that the facilities, equipment, instructions and safety 
level of the laboratories are on an excellent level. This is a necessity for high-quality research. The group 
and project meetings and seminars are meant mainly for sharing information from the scientific 
problems and results, but also function as an excellent arena to practice presentation skills. 
 RC’s strengths and challenges related to leadership and management, and the actions planned for 
developing the processes. 
In order to better share knowledge and assist each other within the RC, there is also a plan to start a 
knowledge data bank, where the areas of expertise of all RC members are presented. In a recent 
external evaluation the RC got very positive feedback on our structured and well-functioning 
management and good and open atmosphere that ensures successful research projects. The pointed-
out area to improve was that the RC is very good in making decisions, but poor in acting as decided. This 
concerns the whole staff. The information delivery between the groups could be better. 
 
 
 
 Listing of the RCs external competitive funding, where: 
- the funding decisions have been made during 1.1.2005-31.12.2010, and 
- the administrator of the funding is/has been the University of Helsinki 
 
 Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC 
members during 1.1.2005-31.12.2010: 1300000 
 
 Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) 
TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 3340000 
 
 European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members 
during 1.1.2005-31.12.2010: 350000 
 
 European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the 
RC members during 1.1.2005-31.12.2010: 0 
 
 International and national foundations – names of international and national foundations which have 
decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their 
funding (in euros).  
- names of the foundations: Alfred Kordelin Foundation 
- Center for International Mobility (CIMO) 
- Eemil Aaltosen säätiö 
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- Finnish Concordia Fund 
- Finnish Cultural Foundation 
- Finnish Pharmaceutical Society 
- Foundation for Finnish Inventions 
- Fulbright Center 
- Jenny ja Antti Wihuri Foundation 
- New Zealand Pharmacy Education and Research Foundation 
- Nordforsk 
- Research Foundation of the University of Helsinki 
- Suomalais-ranskalainen teknistieteellinen seura 
- University of Helsinki / Chancelor (travel grant) 
- Yliopiston apteekin 250-vuotisjuhlarahasto 
- total amount of funding (in euros) from the above-mentioned foundations: 630000 
 
 Other international funding - names of other international funding organizations which have decided to 
allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in 
euros). 
- names of the funding organizations: American Association of Pharmaceutical Scientists (AAPS) 
- Astra Zeneca 
- Bayer Schering Pharma 
- Boehringer-Ingelheim 
- China Scholarship Council 
- University of Kentucky, USA 
- total amount of funding (in euros) from the above-mentioned funding organizations: 390000 
 
 Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral 
programme positions) - names of other national funding organizations which have decided to allocate 
funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros). 
- names of the funding organizations: Graduate School in Pharmaceutical Research 
- Novagent Oy 
- Orion Pharma 
- University of Helsinki / Chancelor (travel grant) 
- Åbo Akademi 
- total amount of funding (in euros) from the above-mentioned funding organizations: 1950000 
 
 
 
 Description of the RC’s future perspectives in respect to research and doctoral training. 
RC’s future perspectives in research: 
The goal of the RC is to promote scientific excellence in the fields of applied materials sciences and solid 
dosage forms. To accomplish this, the RC will identify and promote multidisciplinary research on 
essential topics in pharmaceutical technology. 
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It is foreseen, that preclinical formulation research should continue to be the essential part of our 
research. Development of new formulation technologies can lead to faster and higher-quality 
pharmaceutical formulation design and deeper molecular-level understanding of the relevant 
formulation issues. This will assure that all theoretical therapeutic potential of new drug candidates can 
be effectively exploited. 
 
PARTICLE RC’s research fields will be: Development of novel drug delivery systems, Pediatric and 
veterinary drug formulations, Early ADME, Pharmaceutical materials research, and Physical process 
research including Process analytical technologies. Important, underlying, aim will be continuous 
development towards nanotechnological approaches and individual medication. 
  
In the coming years the RC aims to maintain high productivity and educate annually four Ph.D. theses, 
file for three patents and/or patent applications, and twenty original high level scientific publications. 
Special attention will be paid in the publishing forums and research quality. 
 
Since practically all the research in the RC is done by short-midterm external funding, it is necessary to 
find ways to strengthen the long-term funding. Especially the RC should cooperate more with its current 
EU partners and get more research funding together with them. The total amount of external funding 
should be increased by twenty percent in the coming three years period. 
 
Collaboration with our own earlier students (for example six professors abroad) should be strengthened. 
It would be beneficial to select high-level international prime partners with whom the future research 
and students mobility will be mainly developed. These negotiations will be started within the 
Pharmaceutical Solid State Research Cluster. 
 
Today the research in the RC is based on the three research areas (the three Professors’ groups). 
Cooperation between these groups has been too much based in Professors’ steering meetings. In future, 
direct cooperation between the researchers will be encouraged.  
 
RC’s future perspectives in doctoral training: 
Our doctoral training has been successful. During the evaluation period totally22 Ph.D. degrees were 
achieved. However, there are still great challenges in the future in doctoral training; especially the Ph.D. 
student's mobility and security of long-term funding should be improved.  Hoverer, we believe that with 
individual care taking of the students, more clear leadership based on high ethics and our own specific 
scientific expertise and international networking, the challenges can be turned to the RC’s progress and 
welfare. 
 
Important fields in the doctoral training to be developed are: 
• Arrange a standard six-month training period abroad for the RC's Ph.D. students  
• The RC is aiming at getting EU's funding, e.g. Marie Curie funding to improve doctoral training, which 
increases joint courses and students mobility 
• The RC will build its employment follow-up system for recently graduated students 
• RC will build its own alumni program 
• Industrial pharmacy licentiate students will be incorporated more tightly into the RC 
• Ph.D. and M.Sc. student seminars will be developed further 
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A special evaluation team consisting of two Professors and four University Lecturers was made. The 
responsible person, Professor Jouko Yliruusi, was the team leader. In the first project evaluation team 
meeting, discussion and draft writing responsibilities were divided amongst all the participants. Also an 
information manager was named to keep the whole division up-to-date during the data collection 
phase. 
 
In the beginning of the actual application text production, the separate subgroups worked quite 
independently. However, throughout the compiling of the evaluation documentation the groups were 
recommended to take into account researchers’ opinions and help as widely as reasonable. When the 
individual parts were almost finished, they were cross-commented by numerous researchers and Ph.D. 
students in the RC.  
 
The final compiling of the evaluation documents was made by the three Professors in the RC. After final 
corrections and suggestions the documentation was submitted. 
9 SHORT DESCRIPTION OF HOW THE RC MEMBERS HAVE CONTRIBUTED TO THE COMPILATION OF THE STAGE 2 
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1 Analysis of publications 
 
- Associated person is one of Sari Airaksinen ,  Hélder A. Santos ,  Osmo Antikainen , 
 Leena Christiansen, Jyrki Heinämäki ,  Jouni Hirvonen ,  Anne Juppo , 
Niina Kivikero ,  Timo Laaksonen ,  Satu Lakio , Leena Peltonen , 
 Jukka Tapio Rantanen ,  Niklas Sandler ,  Mia Siven ,  Clare 
Strachan, Jouko Yliruusi ,  Jaakko Aaltonen ,  Samuli Hirsjärvi ,  Inna Miroshnyk , 
 Meike Römer, Henna Vihola, Luis Maria Bimbo ,  Henrik Ehlers ,  Jaana Katriina Hautala , 
 Petteri Heljo ,  Ruzica Kolakovic ,  Johanna Raiman , Kirsi 
Rosenqvist ,  Anna Shevchenko ,  Anne Soikkeli ,  Ira Soppela , 
 Maria Tahvanainen ,  Hanna Katriina Valo , 
 
Publication year 
Publication type 2005 2006 2007 2008 2009 2010 
Total Count 2005 - 
2010 
A1 Refereed journal article 16 16 37 28 22 26 145 
A2 Review in scientific journal 2  1 3 1 4 11 
A3 Contribution to book/other compilations (refereed) 2  3 5 6  16 
A4 Article in conference publication (refereed) 7 13 5 18 13 4 60 
B1 Unrefereed journal article 1   1  1 3 
B3 Unrefereed article in conference proceedings     1  1 
C1 Published scientific monograph 1      1 
D1 Article in professional journal   1   1 2 
D3 Article in professional conference proceedings 1      1 
E1 Popular article, newspaper article 1      1 
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2 Listing of publications 
 
 
A1 Refereed journal article 
2005 
Airaksinen, S, Karjalainen, M, Shevchenko, A, Westermarck, S, Leppänen, E, Rantanen, J, Yliruusi, J  2005, 'Role of water in the 
physical stability of solid dosage formulations', Journal of Pharmaceutical Sciences, vol 10, pp. 2147-2165. 
Airaksinen, S, Karjalainen, M, Kivikero, N, Westermarck, S, Shevchenko, A, Rantanen, J, Yliruusi, J 2005, 'Excipient selection can 
significantly affect solid-state phase transformation in formulation during wet granulation', AAPS PharmSciTech. 
Bonsdorff-Nikander, AV, Christiansen, L, Huikko, L, Lampi, A, Piironen, V, Yliruusi, J, Kaukonen, AM 2005, 'A comparison of the effect 
of medium- vs. long-chain triglycerides on the in vitro solubilization of cholesterol and/or phytosterol into mixed micelles', Lipids, vol 40, 
no. 2, pp. 181-190. 
Fernandez Cervera, M, Heinämäki, J, Salgado-Rodriguez, E, Antikainen, O, Iraizoz Colarte, A, Yliruusi, J  2005, 'Effective optimization of 
enteric film coating of pellets with a miniaturized top-spray coater', Pharmazeutische Industrie., vol 67, no. 2, pp. 231-236. 
Gonzales Novoa, G, Heinämäki, J, Mirza, S, Antikainen, O, Iraizoz Colarte, A, Suzarte Paz, A, Yliruusi, J  2005, 'Physical solid-state 
properties and dissolution of sustained-release matrices of polyvinylacetate',  European Journal of Pharmaceutics and 
Biopharmaceutics, vol 59, pp. 343-350. 
Hyvönen, S, Peltonen, L, Karjalainen, M, Hirvonen, J 2005, 'Effect of nanoprecipitation on the physicochemical properties of low 
molecular weight poly(L-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone dipropionate', International 
Journal of Pharmaceutics, vol 295, no. 1/2, pp. 269-281. 
Häkkinen, A, Pöllänen, K, Karjalainen, M, Rantanen, J, Louhi-Kultanen, M, Nyström, L 2005, 'Batch cooling crystallization and pressure 
filtration of sulphathiazole: the influence of solvent composition',  Biotechnology and Applied Biochemistry, vol 41, no. 1, pp. 17-28. 
Hänninen, K, Kaukonen, AM, Murtomäki, LS, Hirvonen, J 2005, 'Effect of ion-exchange fiber structure on the binding and release of 
model salicylates', Journal of Pharmaceutical Sciences, vol 94, no. 8, pp. 1772-1781. 
Karjalainen, M, Airaksinen, S, Rantanen, J, Aaltonen, J, Yliruusi, J 2005, 'Characterization of polymorphic solid-state changes using 
variable temperature X-ray powder diffraction',  Journal of Pharmaceutical and Biomedical Analysis, vol 39, no. 1/2, pp. 27-32. 
Katajavuori, N, Lindblom-Ylänne, S, Hirvonen, J 2005, 'Pharmacy mentors' views of practical training', Research in Science 
Education, vol 35, no. 2-3, pp. 323-345. 
Luukkanen, L, Taskinen, J, Kurkela, M, Kostiainen, R, Hirvonen, J, Finel, M 2005, 'Kinetic characterization of the 1A subfamily of 
recombinant human UDP-glucuronosyltransferases', Drug Metabolism and Disposition, vol 33, no. 7, pp. 1017-1026. 
Rantanen, J, Wikström, H, Turner, R, Taylor, L 2005, 'Use of in-line near-infrared spectroscopy in combination with chemometrics for 
improved understanding of pharmaceutical processes', Analytical Chemistry, vol 77, no. 2, pp. 556-563. 
Salonen, J, Laitinen, L, Kaukonen, AM, Tuura, J, Bjökqvist, M, Heikkilä, T, Vähä-Heikkilä, K, Hirvonen, J, Lehto, V 2005, 'Mesoporous 
silicon microparticles for oral drug delivery: Loading and release of five model drugs', Journal of Controlled Release, vol 108, pp. 362-
374. 
Sandler, N, Rantanen, J, Heinämäki, J, Römer, M, Marvola, M, Yliruusi, J 2005, 'Pellet manufacturing by extrusion-spheronization using 
process analytical technology', AAPS PharmSciTech, vol 6, no. 2. 
Sipilä, J, Nurmi, H, Kaukonen, AM, Hirvonen, J, Taskinen, J, Yli-Kauhaluoma, J 2005, 'A modification of the Hammett equation for 
predicting ionisation constants of p-vinyl phenols', European Journal of Pharmaceutical Sciences, vol 25, no. 4-5, pp. 417-425. 
Vihola, H, Laukkanen, A, Valtola, L, Tenhu, H, Hirvonen, J 2005, 'Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), 
poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam)', Biomaterials, vol 26, no. 16, pp. 3055-3064. 
 
 
2006 
Aaltonen, J, Heinänen, P, Peltonen, L, Kortejärvi, H, Tanninen, VP, Christiansen, L, Hirvonen, J, Yliruusi, J, Rantanen, J 2006, 'In situ 
measurement of solvent-mediated phase transformations during dissolution testing',  Journal of Pharmaceutical Sciences, vol 95, pp. 
2730-2737. 
Gil, E, Colarte, A, Bataille, J, Rodriguez, F, Heinämäki, J 2006, 'Development and optimization of a novel sustained-release dextran 
tablet formulation for propranolol hydrochloride', International Journal of Pharmaceutics, vol 317, pp. 32-39. 
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Hautamäki, M, Hirvonen, J, Airaksinen, M 2006, 'Farmaseuttien työssä viihtyminen ja unelmatyöura', Dosis, vol 22, no. 3, pp. 193-204. 
Hautamäki, M, Hirvonen, J, Airaksinen, M 2006, 'Farmaseuttien sijoittuminen työelämään: koulutuksen ja työelämän vastaavuus', 
Dosis, vol 22, no. 3, pp. 183-192. 
Hirsjärvi, S, Peltonen, L, Kainu, L, Hirvonen, J 2006, 'Freeze-drying of low molecular weight poly(L-lactic acid) nanoparticles : effect of 
cryo- and lyoprotectants', Journal of Nanoscience and Nanotechnology, vol 6, pp. 3110-3117. 
Hirsjärvi, S, Peltonen, L, Hirvonen, J 2006, 'Layer-by-layer polyelectrolyte coating of low molecular weight poly(lactic acid) 
nanoparticles', Colloids and Surfaces B: Biointerfaces, vol 49, no. 1, p. 93-99s. 
Jorgensen, AC, Miroshnyk, I, Karjalainen, M, Jouppila, K, Siiriä, S, Antikainen, O, Rantanen, J 2006, 'Multivariate data analysis as a fast 
tool in evaluation of solid state phenomena', Journal of Pharmaceutical Sciences, vol 95, pp. 906-916. 
Katajavuori, N, Lindblom-Ylänne, S, Hirvonen, J 2006, 'The significance of practical training in linking theoretical studies with practice', 
Higher Education, vol 51, no. 3, pp. 439-464. 
Koljonen, M, Hakala, K, Ahola-Sätilä, T, Laitinen, L, Kostiainen, R, Kotiaho, T, Kaukonen, AM, Hirvonen, J 2006, 'Evaluation of cocktail 
approach to standardise Caco-2 permeability experiments', European Journal of Pharmaceutics and Biopharmaceutics, vol 64, no. 
3, pp. 379-387. 
Miroshnyk, I, Khriachtchev, L, Mirza, S, Rantanen, J, Heinämäki, J, Yliruusi, J 2006, 'Insight into thermally induced phase 
transformations of erythromycin A dihydrate', Crystal Growth & Design, vol 6, no. 2, pp. 369-374. 
Mirza, S, Heinamaki, J, Miroshnyk, I, Rantanen, J, Christiansen, L, Karjalainen, M, Yliruusi, J 2006, 'Understanding processing-induced 
phase transformations in erythromycin - PEG 6000 solid dispersions', Journal of Pharmaceutical Sciences, vol 95, no. 8, pp. 1723-
1732. 
Pöllänen, K, Häkkinen, A, Reinikainen, S, Rantanen, J, Minkkinen, P 2006, 'Dynamic PCA-based MSPC charts for nucleation prediction 
in batch cooling crystallization processes', Chemometrics and Intelligent Laboratory Systems. 
Rantanen, J 2006, 'Terahertz applications for the analysis of solid dosage forms', Pharmaceutical Technology Europe. 
Seitavuopio, P, Heinämäki, J, Rantanen, J, Yliruusi, J 2006, 'Monitoring tablet surface roughness during the film coating process', AAPS 
PharmSciTech. 
Strachan, CJ, Zeitler, JA, Kogermann, K, Rades, T, Aaltonen, J, Rantanen, J  2006, 'Better understanding of drug dehydration through 
terahertz pulsed spectroscopy', European Journal of Pharmaceutical Sciences, vol 28, pp. S16-S16. 
Säkkinen, MS, Marvola, J, Kanerva, H, Lindevall, K, Ahonen, A, Marvola, M 2006, 'Are chitosan formulations mucoadhesive in the 
human small intestine? An evaluation based on gamma scintigraphy',  International Journal of Pharmaceutics, vol 307, no. 2, pp. 285-
291. 
2007 
Aaltonen, J, Strachan, C, Pöllänen, K, Yliruusi, J, Rantanen, J 2007, 'Hyphenated spectroscopy as a polymorph screening tool', Journal 
of Pharmaceutical and Biomedical Analysis, vol 44, no. 2, pp. 477-483. 
Aaltonen, J, Kogermann, K, Strachan, C, Rantanen, J 2007, 'In-line monitoring of solid-state transitions during fluidisation', Chemical 
Engineering Science. 
Antikainen, O, Kachrimanis, K, Malamataris, S, Yliruusi, J, Sandler, N  2007, 'Image analysis by pulse coupled neural networks (PCNN) - 
a novel approach in granule size characterization', Journal of Pharmacy and Pharmacology, vol 59, no. 1, pp. 51-57. 
Hanninen, K, Kaukonen, AM, Murtomaki, L, Hirvonen, J 2007, 'Mechanistic evaluation of factors affecting compound loading into ion-
exchange fibers', European Journal of Pharmaceutical Sciences, vol 31, no. 5, pp. 306-317. 
Heikkilä, T, Salonen, J, Tuura, J, Hamdy, M, Mul, G, Kumar, N, Salmi, T, Murzin, D, Laitinen, L, Kaukonen, AM, Hirvonen, J, Lehto, V 
2007, 'Mesoporous silica material TUD-1 as a drug delivery system', International Journal of Pharmaceutics, vol 331, no. 1, pp. 133-
138. 
Heikkilä, T, Salonen, J, Tuura, J, Kumar, N, Salmi, T, Murzin, D, Hamdy, M, Mul, G, Laitinen, L, Kaukonen, AM, Hirvonen, J, Lehto, V 
2007, 'Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery',  Drug Delivery, 
vol 14, no. 6, pp. 337-347. 
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containing betulin for inhalation administration', Pharmaceutical Chemistry Journal, vol 44, no. 9, pp. 501-503. 
Kartal, A, Marvola, J, Matheka, J, Peltoniemi, M, Siven, M 2010, 'Computational prediction of local drug effect on carcinogenic 
acetaldehyde in the mouth based on in vitro/in vivo results of freely soluble L-cysteine',  Drug Development and Industrial Pharmacy, 
vol 36, no. 6, pp. 715-723. 
Laaksonen, P, Kainlauri, M, Laaksonen, T, Shchepetov, A, Jiang, H, Ahopelto, J, Linder, MB 2010, 'Interfacial Engineering by Proteins: : 
Exfoliation and Functionalization of Graphene by Hydrophobins', Angewandte Chemie (International Edition), vol 49, no. 29, pp. 
4946-4949. 
Lakio, S, Heinämäki, J, Yliruusi, J 2010, 'Colorful drying', AAPS PharmSciTech, vol 11, no. 1, pp. 46-53. 
Lakio, S, Siiriä, S, Räikkönen, H, Airaksinen, S, Närvänen, T, Antikainen, O, Yliruusi, J 2010, 'New insights into segregation during 
tabletting', International Journal of Pharmaceutics, vol 397, no. 1/2, pp. 19-26. 
Li, XN, Guo, HX, Heinämäki, J 2010, 'Aqueous coating dispersion (pseudolatex) of zein improves formulation of sustained-release 
tablets containing very water-soluble drug', Journal of Colloid and Interface Science, vol 345, no. 1, pp. 46-53. 
Linna, A, Korhonen, M, Airaksinen, MSA, Juppo, A 2010, 'Experiences of using the GMP audit preparation tool in pharmaceutical 
contract manufacturer audits', Drug Development and Industrial Pharmacy, vol 36, no. 6, pp. 632-637. 
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Mirza, S, Miroshnyk, I, Habib, MJ, Brausch, JF, Hussain, MD 2010, 'Enhanced Dissolution and Oral Bioavailability of Piroxicam 
Formulations: Modulating Effect of Phospholipids', Pharmaceutics, vol 2, no. 4, pp. 339-350. 
Pinto, V, Ferreira, M, Silva, R, Santos, HA, Silva, F, Pereira, C 2010, 'Long time effect on the stability of silver nanoparticles in aqueous 
medium: Effect of the synthesis and storage conditions', Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol 
364, no. 1-3, pp. 19-25. 
Raekallio, M, Saario-Paunio, E, Rajamäki, MM, Sankari, SM, Siven, MS, Palviainen, M, Peltoniemi, M, Leinonen, M, Honkavaara, MJ, 
Vainio, O 2010, 'Early detection of ketoprofen-induced acute kidney injury in sheep as determined by evaluation of urinary enzyme 
activities', American Journal of Veterinary Research, vol 71, no. 10, pp. 1246-1252. 
Santos, HA, Riikonen, J, Salonen, J, Makila, E, Heikkila, T, Laaksonen, T, Peltonen, L, Lehto, V, Hirvonen, J 2010, 'In vitro cytotoxicity 
of porous silicon microparticles: Effect of the particle concentration, surface chemistry and size',  Acta Biomaterialia, vol 6, pp. 2721-
2731. 
Santos, AO, Gomes da Silva, LC, Bimbo, LM, Pedroso de Lima, MC, Simões, S, Moreira, JN 2010, 'Design of peptide-targeted 
liposomes containing nucleic acids', Biochimica et Biophysica Acta. Biomembranes, vol 1798, no. 3, pp. 433-441. 
Seppälä, K, Heinämäki, J, Hatara, J, Seppälä, L, Yliruusi, J 2010, 'Development of a New Method to Get a Reliable Powder Flow 
Characteristics Using Only 1 to 2 g of Powder', AAPS PharmSciTech, vol 11, pp. 402-408. 
Siissalo, S, Laine, L, Tolonen, A, Kaukonen, AM, Finel, M, Hirvonen, J  2010, 'Caco-2 cell monolayers as a tool to study simultaneous 
phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol', International Journal of Pharmaceutics, vol 
383, no. 1-2, pp. 24-29. 
Soikkeli, A, Sempio, C, Kaukonen, AM, Urtti, A, Hirvonen, J, Yliperttula, M 2010, 'Feasibility Evaluation of 3 Automated Cellular Drug 
Screening Assays on a Robotic Workstation', Journal of Biomolecular Screening, vol 15, pp. 30-41. 
Valo, HK, Laaksonen, PH, Peltonen, LJ, Linder, MB, Hirvonen, JT, Laaksonen, TJ 2010, 'Multifunctional Hydrophobin: : Toward 
Functional Coatings for Drug Nanoparticles', ACS nano., vol 4, no. 3, pp. 1750-1758. 
Virtanen, S, Antikainen, O, Räikkönen, H, Yliruusi, J 2010, 'Granule Size Distribution of Tablets', Journal of Pharmaceutical Sciences, 
vol 99, no. 4, pp. 2061-2069. 
A2 Review in scientific journal 
2005 
Hirvonen, J 2005, 'Topical iontophoretic delivery: progress to date and therapeutic potential', American journal of drug delivery, vol 3, 
no. 2, pp. 67-81. 
Kaukonen, AM, Hirvonen, J 2005, 'Lääkekandidaatin kehityskelpoisuuden arviointi', Dosis, vol 21, no. 1, pp. 58-76. 
2007 
Lee, C, Strachan, C, Manson, P, Rades, T 2007, 'Characterization of the bulk properties of pharmaceutical solids using nonlinear optics: 
a review', Journal of Pharmacy and Pharmacology, vol 59, no. 2, pp. 241-250. 
2008 
Laaksonen, T, Ruiz, V, Liljeroth, P, Quinn, BM 2008, 'Quantised charging of monolayer-protected nanoparticles', Chemical Society 
Reviews, vol 37, no. 9, pp. 1836-1846. 
Peltonen, L, Hirvonen, J 2008, 'Physicochemical characterization of nano- and microparticles', Current Nanoscience, vol 4, pp. 101-
107. 
Salonen, J, Kaukonen, AM, Hirvonen, J, Lehto, V 2008, 'Mesoporous silicon in drug delivery applications', Journal of Pharmaceutical 
Sciences, vol 97, no. 2, pp. 632-653. 
2009 
Miroshnyk, I, Mirza, S, Sandler, N 2009, 'Pharmaceutical co-crystals-an opportunity for drug product enhancement', Expert Opinion on 
Drug Delivery, vol 6, no. 4, pp. 333-341. 
2010 
Miroshnyk, I, Mirza, S 2010, 'Capturing the advantages of co-crystals', Pharmaceutical Technology Europe, vol 22, no. 7, pp. 31-34. 
Peltonen, L, Valo, H, Kolakovic, R, Laaksonen, T, Hirvonen, J 2010, 'Electrospraying, spray drying and related techniques for production 
and formulation of drug nanoparticles', Expert Opinion on Drug Delivery, vol 7, no. 6, pp. 705-719. 
Peltonen, L, Hirvonen, J 2010, 'Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and 
stabilization methods', Journal of Pharmacy and Pharmacology, vol 62, no. 11, pp. 1569-1579. 
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Santos, HA, García-Morales, V, Pereira, C 2010, 'Electrochemical Properties of Phospholipid Monolayers at Liquid–Liquid Interfaces', 
ChemPhysChem, vol 11, no. 1, pp. 28-41. 
A3 Contribution to book/other compilations (refereed) 
2005 
Katajavuori, N, Kuosa, T, Hirvonen, J 2005, 'Assessing the quality of pharmacy education: a study proposal for developing the 
pharmacy education and teaching in bachelor's degree', Research-Based teaching in higher education. seminar March 22-23, 2005 
University of Helsinki., Helsingin yliopisto, Valtiotieteellinen tiedekunta, Helsinki, pp. 45-48. 
Toropainen, T, Jarho, P, Järvinen, K, Vihola, H, Hirvonen, J, Järvinen, T  2005, 'Cyclodextrins in pulmonary drug delivery', Polymorfi, 
Helsinki, pp. 18-20. 
2007 
Heikkilä, T, Salonen, J, Tuura, J, Kumar, N, Salmi, T, Murzin, D, Hamdy, M, Mul, G, Laitinen, L, Kaukonen, AM, Hirvonen, J, Lehto, V 
2007, 'Evaluation of mesoporous TCPSi, MCM-41, SBA-15 and TUD-1 materials as oral drug delivery systems',  Transactions, The 
Society cop., Minneapolis, MN. 
Peltonen, L, Hannukainen, J, Mäkeläinen, S, Hirvonen, J 2007, 'Effect of particle size on solubility properties of Ibuprofen powder: 
nanocrystallization by ball-milling', Transactions, The Society cop., Minneapolis, MN. 
Valo, H, Peltonen, L, Karjalainen, M, Kostiainen, R, Hirvonen, J 2007, 'Formulation of drug loaded nanoparticles from low molecular 
weight poly(L-Lactic Acid) by a novel electrospraying technique',  Transactions, The Society cop., Minneapolis, MN. 
2008 
Heikkilä, T, Sandos, H, Salonen, J, Riikonen, J, Mäkilä, E, Laaksonen, T, Peltonen, L, Kumar, N, Murzin, D, Salmi, T, Hirvonen, J, 
Lehto, V 2008, 'Mesoporous silicon and silica as carrier materials for oral delivery of poorly soluble drugs: cytotoxicity and formulation 
compatibility', Responding to global needs through delivery science. 2008.. 
Järvinen, K, Pulkkinen, M, Hirvonen, J, Hirsjärvi, S, Peltonen, L 2008, 'Preparation and characterization of polymetric nanoparticles and 
microparticles for pharmaceutical applications', Handbook of particulate drug delivery, American Scientific Publishers cop., 
Stevenson Ranch, Ca, pp. 17-34. 
Kettunen, R, Peltonen, L, Karjalainen, M, Hirvonen, J 2008, 'Nanosizing indomethacin by wet ball-milling technique: an efficient method 
to improve the solubility properties of the poorly soluble NSAID', Responding to global needs through delivery science. 2008.. 
Larsson, A, Abrahamsen-Alami, A, Juppo, A 2008, 'Oral extended-release formulations', in M Leventhal, SC Gad (eds), 
Pharmaceutical Manufacturing Handbook, Production and Processes, John Wiley & Sons, pp. 1191-1222. 
Lehto, P, Hirvonen, J, Peltonen, L 2008, 'Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal 
fluid and fasted state simulated intestinal fluid',  Responding to global needs through delivery science. 2008.. 
2009 
Heikkilä, T, Peltonen, L, Taskinen, S, Laaksonen, T, Hirvonen, J 2009, 'Microtensiometry: novel surface tension based HTS method for 
solubility testing of drug materials', New progresses and challenges in pharmaceutical sciences / Edited by. A. Atilla Hincal, Nevin 
Celebi, Nilufer Yuksel., TUFTAD Pharmaceutical Sciences Series, Turkish Pharmaceutical Technology Scientists Association 
(TUFTAD),, Ankara, pp. 86-94. 
Laaksonen, T, Laaksonen, H, Murtomäki, L, Hirvonen, J 2009, 'Cellular automata model for drug release simulations', New progresses 
and challenges in pharmaceutical sciences / Edited by. A. Atilla Hincal, Nevin Celebi, Nilufer Yuksel., TUFTAD Pharmaceutical 
Sciences Series, Turkish Pharmaceutical Technology Scientists Association (TUFTAD),, Ankara, pp. 76-85. 
Laaksonen, T, Laaksonen, H, Hirvonen, J, Murtomäki, L 2009, 'Cellular automata model for swelling-controlled drug release', 
Transactions Controlled Release Society, Controlled Release Society,, Minneapolis, MN. 
Lehto, V, Hirvonen, J, Järvinen, K, Herzig, K, Louhi-Kultanen, M, Närvanen, A, Salonen, J 2009, 'Feasibility of mesoporous silicon as a 
functional drug carrier', Transactions Controlled Release Society, Controlled Release Society,, Minneapolis, MN. 
Riikonen, J, Santos, HA, Mäkilä, E, Salonen, J, Hirvonen, J, Lehto, V 2009, 'The Physical state and dissolution of drug molecules in 
mesoporous silicon', Transactions Controlled Release Society, Controlled Release Society,, Minneapolis, MN. 
Santos, HA, Riikonen, J, Heikkilä, T, Salonen, J, Laaksonen, T, Peltonen, L, Lehto, V, Hirvonen, J 2009, 'Toxicity of nano- and micro-
sized porous silicon in human intestine epithelial cells', Transactions Controlled Release Society, Controlled Release Society,, 
Minneapolis, MN. 
A4 Article in conference publication (refereed) 
2005 
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Aaltonen, J, Evendi, K, Heinämäki, J, Veski, P, Yliruusi, J, Rantanen, J 2005, 'An insight into dehydration phenomena', in Proceedings 
of the 1st BBBB Conference on Pharmaceutical Sciences. 
Hyvönen, S, Peltonen, L, Hirvonen, J 2005, 'Layer-by-layer coating of polystyrene nanoparticles', in Proceedings of the 1st BBBB 
Conference on Pharmaceutical Sciences. 
Miroshnyk, I, Heinämäki, J, Räsänen, E, Mirza, S, Karjalainen, M, Rantanen, JT, Yliruusi, J 2005, In-line monitoring of drying behaviour 
of erythromycin pellets,, Paper presented at 1st PharmSciFair, Nice, France. 12. - 17. June, 2005.. 
Miroshnyk, I, Mirza, S, Rantanen, JT, Heinämäki, J, Yliruusi, J 2005, 'In situ Monitoring of Thermally-Induced Phase Transformations of 
Erythromycin Dihydrate', in Electronical Proceedings (CD-Rom) of the 1st PharmSciFair. 
Mirza, S, Miroshnyk, I, Rantanen, JT, Heinämäki, J, Antikainen, O, Vuorela, P, Vuorela, H, Yliruusi, J  2005, 'Controlling the crystal habit: 
effect of excipients', in Electronical Proceedings (CD-Rom) of the 1st PharmSciFair. 
Mirza, S, Miroshnyk, I, Rantanen, JT, Heinämäki, J, Antikainen, O, Vuorela, P, Vuorela, H, Yliruusi, J  2005, 'Crystal engineering of 
erythromycin using hydroxypropyl methylcellulose', in Electronical Proceedings (CD-Rom) of the 1st PharmSciFair. 
Qu, H, Mirza, S, Louhi-Kultanen, M, Rantanen, JT, Kallas, J 2005, Study on Hydrate Formation of Carbamazepine Based on in-line 
Raman Spectroscopy and Videomicroscopy,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) 
Annual Meeting and Exposition, Nashville, United States. AAPS Journal 7 S2 SPRINGER NEW YORK LLC. 
2006 
Aaltonen, J, Kogermann, K, Strachan, CJ, Rantanen, J 2006, In-line monitoring of solid-state transformations during fluidisation,, 
European Journal of Pharmaceutical Sciences 28 ELSEVIER BV. 
Aaltonen, J, Peltonen, L, Hirvonen, J, Rantanen, J 2006, 'Can solid-state analysis solve the problem of anomalous dissolution profiles?', 
in 5rd World Meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology. 
Haikola, M, Simpura, I, Penate Medina, O, Hirvonen, J, Peltonen, L 2006, 'Microtensiometry - a useful tool to determine critical micelle 
concentration and solubility properties of amphiphilic peptide derivatives', in 5rd World Meeting on pharmaceutics, 
biopharmaceutics and pharmaceutical technology. 
Haikola, M, Hirvonen, J, Simpura, I, Penate Medina, O, Peltonen, L 2006, 'Solvent effects on micelle formation of an amphiphilic peptide 
derivative - microtensiometric determinations', in 33rd Annual Meeting of Exposition of the Controlled Release: Controlled Release 
Society 2006. 
Heinanen, P, Aaltonen, J, Niemela, P, Rantanen, J, Yliruusi, J, Tanninen, VP 2006, Simultaneous measurement of dissolved amount of 
drug and solid phase composition during intrinsic dissolution testing,, European Journal of Pharmaceutical Sciences 28 ELSEVIER BV. 
Hirsjärvi, S, Laitinen, L, Hirvonen, J 2006, 'Layer- by-layer coating of low molecular weight poly(L-lactic acid) nanoparticles', in 
Opportunities and challenges for nanotechnology products: 2006. 
Hirsjärvi, S, Peltonen, L, Hirvonen, J 2006, 'Sequential layer-by-layer adsorption of polyelectrolytes on low molecular weight poly(Llactic 
acid) nanoparticles', in 33rd Annual Meeting of Exposition of the Controlled Release: Controlled Release Society 2006. 
Hyvönen, S, Peltonen, L, Hirvonen, J 2006, 'Layer-by-layer polyelectrolyte coating of poly(lactic acid) nanoparticles: role of the solvent 
selection during nanoparticle preparation', in 5rd World Meeting on pharmaceutics, biopharmaceutics and pharmaceutical 
technology. 
Kaukonen, AM, Laitinen, L, Salonen, J, Paski, J, Heikkilä, T, Hirvonen, J, Lehto, V 2006, 'Enhanced in vitro dissolution and permeation 
of furosemide loaded into porous silicon microparticles', in 33rd Annual Meeting of Exposition of the Controlled Release: 
Controlled Release Society 2006. 
Kaukonen, AM, Laitinen, L, Salonen, J, Paski, J, Heikkilä, T, Hirvonen, J, Lehto, V 2006, 'Enhanced in vitro dissolution and permeation 
of furosemide loaded into porous silicon microparticles', in 33rd Annual Meeting of Exposition of the Controlled Release: 
Controlled Release Society 2006. 
Kogermann, K, Aaltonen, J, Strachan, C, Veski, P, Heinamaki, J, Yliruusi, J, Rantanen, J 2006, Monitoring of diverse hydrates using 
NIR and Raman spectroscopy - Quantitative modelling of complex and simple systems,, European Journal of Pharmaceutical Sciences 
28 ELSEVIER BV. 
Mirza, S, Miroshnyk, I, Heinämäki, J, Yliruusi, J, Hussain, M 2006, Physical Characterization and in Vivo Evaluation of Mifepristone - 
Polyethylene Glycol Solid Dispersions,, Paper presented at 18th Helsinki Drug Research, Helsinki, Finland. 01. June, 2006 - 15. 
September, 2007. European Journal of Pharmaceutical Sciences 28 Supplement 1 ELSEVIER BV. 
Salonen, J, Tuura, J, Björkqvist, M, Heikkilä, T, Laitinen, L, Kaukonen, AM, Hirvonen, J, Lehto, V 2006, 'Controlling dissolution 
behaviour of drug compounds by mesoporous silicon microparticles', in 5rd World Meeting on pharmaceutics, biopharmaceutics 
and pharmaceutical technology. 
2007 
Haapalainen, J, Kassamakov, I, Heinämäki, J, Hæggström, E, Yliruusi, J 2007, 'FEM prediction of dynamic scratch resistance of 
polymer coatings', in 20th Annual ABAQUS Users Conference. 
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Mirza, S, Miroshnyk, I, Heinämäki, J, Rantanen, JT, Antikainen, O, Vuorela, P, Vuorela, H, Yliruusi, J  2007, HPMC-controlled 
crystallization of erythromycin A dihydrate with improved compaction properties,, Paper presented at The 2nd BBBB Conference on 
Pharmaceutical Sciences , Tartu, Estonia. 13. - 15. September, 2007. European Journal of Pharmaceutical Sciences 32 1, 
Supplement 1 ELSEVIER BV. 
Mirza, S, Miroshnyk, I, Heinämäki, J, Rantanen, JT, Yliruusi, J 2007, In situ monitoring of processing-induced transformations using 
optical microscopy,, AAPS Journal 9 S2 SPRINGER NEW YORK LLC. 
Mirza, S, Miroshnyk, I, Heinämäki, J, Rantanen, JT, Antikainen, O, Yliruusi, J 2007, 'Morphological crystal engineering of 
pharmaceutical materials', in Proceedings of the Proceedings of the 1st meeting of the Pharmaceutical Solid State Research 
Cluster (PSSRC). 
Strachan, CJ, Howell, SL, Aaltonen, J, Heinz, A, Kogermann, K, Rantanen, J  2007, Insight into the metastable form of theophylline 
monohydrate using vibrational spectroscopy, computational chemistry and multivariate analysis, , European Journal of Pharmaceutical 
Sciences 32 ELSEVIER BV. 
2008 
Hirsjärvi, S, Helle, A, Peltonen, L, Hirvonen, J, Wiedmer, S 2008, 'Application of capillary electrophoresis in the drug quantification from 
pharmaceutical nanoparticles', in 6th World Meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology . 
Kettunen, R, Hirvonen, J, Peltonen, L 2008, 'Nanonization as a tool to improve the solubility properties NSAIDs: correlation between 
ibuprofen and indomethacin', in 6th World Meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology. 
Laaksonen, T, Limnell, T, Santos, H, Heikkilä, T, Riikonen, J, Salonen, J, Peltonen, L, Lehto, V, Hirvonen, J 2008, 'Drug dissolution 
studies on mesoporous silicon particles: a theoretical approach', in 6th World Meeting on pharmaceutics, biopharmaceutics and 
pharmaceutical technology. 
Miroshnyk, I, Heinämäki, J, Mirza, S, Vuorela, P, Vuorela, H, Yliruusi, J 2008, Amorphous solid dispersions of erythromycin A with 
enhanced acidic stability,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and 
Exposition, Atlanta, United States. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Miroshnyk, I, Heinämäki, J, Mirza, S, Vuorela, P, Vuorela, H, Yliruusi, J 2008, 'Cellulose acetate phthalate as carrier polymer for 
amorphous dispersions with enhanced acidic stability', in  Proceedings of the 6th World Meeting on Pharmaceutics, 
Biopharmaceutics and Pharmaceutical Technology. 
Miroshnyk, I, Mirza, S, Rantanen, JT, Heinämäki, J, Yliruusi, J 2008, Raman spectroscopy as a tool for detecting isomorphic solid phase 
transformations.,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and 
Exposition, Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Miroshnyk, I, Mirza, S, Krasnov, A, Heinämäki, J, Yliruusi, J 2008, Cocrystals: controlling solvent-mediated phase transformations 
during wet granulation.,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and 
Exposition, Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Miroshnyk, I, Mirza, S, Heinämäki, J, Aaltonen, J, Yliruusi, J 2008, Retarding the kinetics of hydrate formation via excipient-mediated 
crystallization.,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 
United States. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Miroshnyk, I, Mirza, S, Heinamaki, J, Aaltonen, J, Yliruusi, J 2008, Retarding the kinetics of theophylline hydrate formation using 
pharmaceutical excipients,, European Journal of Pharmaceutical Sciences 34 ELSEVIER BV. 
Mirza, S, Miroshnyk, I, Peltonen, L, Heinämäki, J, Yliruusi, J 2008, Enhancing dissolution rate of poorly soluble drugs: cocrystal 
approach,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 
Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Mirza, S, Heinamaki, J, Miroshnyk, I, Yliruusi, J 2008, Co-crystals: An emerging approach to improving properties of pharmaceutical 
solids,, Paper presented at Helsinki Drug Research 2008 , Helsinki, Finland. 09. - 11. June, 2008. Dosis 24 2. 
Mirza, S, Miroshnyk, I, Alakurtti, SA, Yli-Kauhaluoma, J, Heinämäki, J, Yliruusi, J 2008, Polymorph screening: effect of solvent on phase 
transformation behavior of betulin,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual 
Meeting and Exposition, Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
Mirza, S, Miroshnyk, I, Heinämäki, J, Rantanen, JT, Antikainen, O, Vuorela, P, Vuorela, H, Yliruusi, J  2008, 'Crystal engineering 
approach to improve tableting performance: the case of erythromycin dihydrate', in  Proceedings of the 6th World Meeting on 
Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology . 
Santos, H, Heikkilä, T, Riikonen, J, Lautenschlager, T, Laaksonen, T, Peltonen, L, Salonen, J, Kumar, N, Murzin, D, Lehto, V, Hirvonen, 
J 2008, 'Investigating cell toxicity and drug dissolution profiles using mesoporous silica and silicon based materials', in 6th World 
Meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology . 
Savolainen, M, Kogermann, K, Heinz, A, Aaltonen, J, Peltonen, L, Strachan, CJ, Yliruusi, J 2008, Improved insight into the dissolution 
behavior of amorphous drugs by in situ solid-state analysis, , European Journal of Pharmaceutical Sciences 34 ELSEVIER BV. 
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Shikov, A, Mirza, S, Miroshnyk, I, Pozharitskaya, O, Urakova, I, Hirsjärvi, S, Makarov, V, Heinämäki, J, Yliruusi, J, Hiltunen, R  2008, 
Freeze-dried nanoparticles for dissolution rate enhancement of poorly water soluble drugs: the case of taxifolin, , Paper presented at 
AAPS Annual Meeting and Exposition, Atlanta, United States. 16. - 20. November, 2008. AAPS Journal 19 S2 SPRINGER NEW 
YORK LLC. 
Soikkeli, A, Sempio, C, Kaukonen, AM, Urtti, A, Hirvonen, J, Yliperttula, M 2008, 'Automation of three different cellular assays on robotic 
workstation: feasibility evaluation', in 6th World Meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology . 
Surov, A, Mirza, S, Miroshnyk, I, Perlovich, G, Bauer-Brandl, A 2008, New insights into polymorphic behavior of flufenamic and 
mefenamic acids.,, Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and 
Exposition, Atlanta, 16. - 20. November, 2008. AAPS Journal 10 S2 SPRINGER NEW YORK LLC. 
2009 
Genina, N, Räikkönen, H, Ehlers, H, Heinämäki, J, Veski, P, Yliruusi, J 2009, 'A new approach to improve flow properties of ibuprofen 
powder', in Electronical Proceedings (CD-Rom) of the European Symposium on Comminution and Classification. 
Heikkilä, T, Mäkilä, E, Ojanen, S, Qu, H, Louhi-Kultanen, M, Riikonen, J, Salonen, J, Kumar, N, Murzin, D, Santos, HA, Laaksonen, T, 
Peltonen, L, Hirvonen, J, Lehto, V 2009, 'Effect of comminution on microparticle properties of mesoporous silicon and silica materials', in 
12th European symposium on comminution and classification (ESCC 2009): 15-18 September 2009, Dipoli Congress Center, 
Espoo, Finland. 
Heinämäki, J, Kassamakov, I, Hanhijärvi, K, Majava, T, Haapalainen, J, Aaltonen, J, Hæggström, E, Yliruusi, J 2009, 'Scratch resistance 
of plasticized hydroxypropyl methylcellulose (HPMC) films intended for tablet coatings', in  Electronical Proceedings (CD-Rom) of the 
European Symposium on Comminution and Classification. 
Heinämäki, J 2009, 'How to measure the flow rate of very poorly flowing powders', in Electronical Proceedings (CD-Rom) of the 
European Symposium on Comminution and Classification. 
Heinämäki, J, Soininen, J, Yliruusi, J  2009, 'Mechanical stress-strain properties of externally plasticized whey protein films', in  
Electronical Proceedings (CD-Rom) of the European Symposium on Comminution and Classification. 
Miroshnyk, I, Mirza, S, Richez, J, Heinämäki, J, Sandler, N 2009, Pharmaceutical cocrystals: assessment of processing performance.,, 
Paper presented at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. AAPS Journal 11 S2 
SPRINGER NEW YORK LLC. 
Mirza, S, Miroshnyk, I, Trows, S, Santos, HA, Peltonen, L, Sandler, N, Heinämäki, J, Yliruusi, J 2009, Pharmaceutical co-crystals as 
molecular-based platform for dissolution rate enhancement of drugs,, Paper presented at PharmSciFair, Nice, France. 08. - 12. June, 
2009.. 
Mirza, S, Miroshnyk, I, Trows, S, Santos, HA, Peltonen, L, Heinämäki, J, Yliruusi, J 2009, Solid-Phase Behaviour of Indomethacin-
Nicotinamide Cocrystals During Dissolution, , Paper presented at American Association of Pharmaceutical Scientists (AAPS) 
Annual Meeting and Exposition, Los Angeles, United States. AAPS Journal 11 S2 SPRINGER NEW YORK LLC. 
Mirza, S, Miroshnyk, I, Trows, S, Santos, H, Peltonen, L, Heinämäki, J, Sandler, N, Yliruusi, J  2009, 'Cocrystal approach to dissolution 
rate modulation of active pharmaceutical ingredients', in Electronical Proceedings (CD-Rom) of the European Symposium on 
Comminution and Classification. 
Mirza, S, Miroshnyk, I, Heinämäki, J, Antikainen, O, Vuorela, P, Vuorela, H, Yliruusi, J 2009, 'Additive-induced crystallization as a tool 
for tailoring tabletting performance of pharmaceutical materials', in Electronical Proceedings (CD-Rom) of the European Symposium 
on Comminution and Classification. 
Peltonen, L 2009, 'Nanoparticles in drug delivery', in 12th European symposium on comminution and classification (ESCC 2009): 
15-18 September 2009, Dipoli Congress Center, Espoo, Finland. 
Seppälä, K, Heinämäki, J, Närvänen, T, Antikainen, O, Räikkönen, H, Yliruusi, J 2009, 'A novel on-line sampling and double-cuvette 
measuring system intended for particle-size and moisture content determination in fluid-bed granulation', in Electronical Proceedings 
(CD-Rom) of the European Symposium on Comminution and Classification. 
Shevchenko, A, Miroshnyk, I, Tiittanen , S, Tanninen , VP, Belle, D, Yliruusi, J  2009, Physical Stability Assessment of the Solid State 
Forms of a New Drug Substance Candidate ORM-10921 HCl.,, Paper presented at American Association of Pharmaceutical 
Scientists (AAPS) Annual Meeting .. 
2010 
Miroshnyk, I, Trows, S, Santos, HA, Peltonen, L, Heinämäki, J, Hussain, M, Yliruusi, J, Mirza, S 2010, 'Linking Dissolution Rate of 
Ibuprofen-Nicotinamide Cocrystals to Thermodynamic Properties of the Coformers', in 37th Annual Meeting and Exposition of the 
Controlled Release Society (CRS). 
Miroshnyk, I, Liu, P, Hussain, M, Yliruusi, J, Mirza, S 2010, Nanococrystals as a formulation alternative for poorly soluble APIs,, Paper 
presented at 2010 FIP Pharmaceutical Sciences World Congress. AAPS Journal 12 S3 SPRINGER NEW YORK LLC. 
Mirza, S, Miroshnyk, I, Mohammadi , G, Alakurtti, SA, Hussain , M, Yli-Kauhaluoma, J, Urtti, A 2010, Electrospinning platform for 
fabrication of monodispersed nanoparticles for pharmaceutical applications,, Paper presented at 2010 FIP Pharmaceutical Sciences 
World Congress, New Orleans, United States. 14. - 18. November, 2010. AAPS Journal 12 S2 SPRINGER NEW YORK LLC. 
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Raula, J, Eerikäinen, H, Peltonen, L, Hirvonen, J, Kauppinen, E 2010, Aerosol-processed polymeric drug nanoparticles for sustained 
and triggered drug release,, Paper presented at European Symposium on Controlled Drug Delivery, Egmond aan zee , 
Netherlands. 07. - 09. April, 2010. Journal of Controlled Release 148 1 ELSEVIER BV. 
B1 Unrefereed journal article 
2005 
Hirvonen, J, Raasmaja, A, Tuominen, R 2005, 'Farmasian tutkijakoulutapaaminen 2005', Dosis, vol 21, no. 3, pp. 206. 
2008 
Hirvonen, J, Laaksonen, T, Peltonen, L, Santos, HA, Lehto, V, Heikkilä, T, Riikonen, J, Mäkilä, E, Salonen, J 2008, 'Feasibility of Silicon-
Based Mesoporous Materials for Oral Drug Delivery Applications', Dosis, vol 24, no. 2, pp. 129-149. 
2010 
Santos, HA, Bimbo, LM, Salonen, J, Lehto, V, Hirvonen, J 2010, 'Tailoring in vitro cell responses of porous silicon micro- and 
nanoparticles', CRS Newsletter, vol 27, no. 1, pp. 10-11. 
B3 Unrefereed article in conference proceedings 
2009 
Heikkilä, T, Peltonen, L, Taskinen, S, Laaksonen, T, Hirvonen, J 2009, Surface tension based kinetic solubility measurements in 96-well 
plates: Proof of concept with ibuprofen and indomethacin,. 
C1 Published scientific monograph 
2005 
Raiman, J 2005, Evaluation of intestinal absorption properties of clodronate using Caco-2 cell culture model, Kuopion yliopisto, 
Kuopio. 
D1 Article in professional journal 
2007 
Juppo, A 2007, 'Lapsille sopivien lääkevalmisteiden erityishaasteita', TABU : lääkeinformaatiota Lääkelaitokselta, vol 15, no. 4, pp. 9-
10. 
2010 
Tuomainen, L, Passi, S, Airaksinen, MSA, Juppo, A, Linden-Lahti, C 2010, 'Ajankohtaiskatsaus farmasian erikoistumiskoulutuksiin ja -
opintoihin Suomessa', Dosis, vol 26, no. 1, pp. 28-30. 
D3 Article in professional conference proceedings 
2005 
Säkkinen, M, Marvola, J, Marvola, M 2005, 'Are chitosan granules mucoadhesive in the human stomach - a gamma scintigraphic study 
in man.', in Proceedings of the 1st BBBB Conference on Pharmaceutical Sciences, pp. 224. 
 
 
E1 Popular article, newspaper article 
2005 
Heinimo, S, Lehtonen, U, Säkkinen, M, Raasmaja, A 2005, 'Vuorovaikutteinen opetus äänestysjärjestelmää käyttäen', Peda-Forum, vol 
12, no. 2, pp. 7-9. 
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1 Analysis of activities 2005-2010 
 
- Associated person is one of Sari Airaksinen ,  Hélder A. Santos ,  Osmo Antikainen , 
 Leena Christiansen, Jyrki Heinämäki ,  Jouni Hirvonen ,  Anne Juppo , 
Niina Kivikero ,  Timo Laaksonen ,  Satu Lakio , Leena Peltonen , 
 Jukka Tapio Rantanen ,  Niklas Sandler ,  Mia Siven ,  Clare 
Strachan, Jouko Yliruusi ,  Jaakko Aaltonen ,  Samuli Hirsjärvi ,  Inna Miroshnyk , 
 Meike Römer, Henna Vihola, Luis Maria Bimbo ,  Henrik Ehlers ,  Jaana Katriina Hautala , 
 Petteri Heljo ,  Ruzica Kolakovic ,  Johanna Raiman , Kirsi 
Rosenqvist ,  Anna Shevchenko ,  Anne Soikkeli ,  Ira Soppela , 
 Maria Tahvanainen ,  Hanna Katriina Valo , 
 
Activity type Count 
Supervisor or co-supervisor of doctoral thesis 57 
Prizes and awards 31 
Editor of research journal 51 
Peer review of manuscripts 107 
Editor of series 1 
Editor of special theme number 4 
Membership or other role in review committee 3 
Membership or other role in research network 6 
Membership or other role in national/international committee, council, board 31 
Membership or other role in public Finnish or international organization 34 
Other tasks of an expert in private sector 1 
Participation in interview for written media 8 
Participation in TV programme 1 
Participation in interview for web based media 2 
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2 Listing of activities 2005-2010 
Supervisor or co-supervisor of doctoral thesis 
Sari Airaksinen ,  
Supervision of Doctoral thesis: Tanja Lipsanen, Sari Airaksinen, 2006  2008 
Supervision of Doctoral thesis: Kirsi Rosenqvist, Sari Airaksinen, 2009  …, Finland 
Supervision of Doctoral thesis: Jaana Hautala, Sari Airaksinen, 2010  …, Finland 
Hélder A. Santos ,  
PhD Thesis Supervision, Hélder A. Santos, 2007  …, Finland 
PhD Thesis Supervision, Hélder A. Santos, 2008  …, Finland 
PhD Thesis Supervision, Hélder A. Santos, 2009  …, Finland 
Osmo Antikainen ,  
Supervision of Doctoral thesis: Tapani Koskenkari, Osmo Antikainen, 2004  2005 
Supervision of Doctoral thesis: Satu Lakio, Osmo Antikainen, 01.01.2005  06.11.2010, Finland 
Supervision of Doctoral thesis, Osmo Antikainen, 01.03.2006  11.12.2008, Finland 
Supervision of Doctoral thesis: Genina Natalja, Osmo Antikainen, 2006  2010, Estonia 
Supervision of Doctoral thesis: Närvänen Tero, Osmo Antikainen, 2006  2008 
Jyrki Heinämäki ,  
Supervisor for PhD studies: Viviana Garcia Mir, Jyrki Heinämäki, 2006, Cuba 
Supervisor for PhD studies: Sabir Uddin Mirza, Jyrki Heinämäki, 2007, Finland 
Supervisor for PhD studies, Jyrki Heinämäki, 2008, Finland 
Supervisor for PhD studies: Karin Kogermann, Jyrki Heinämäki, 2008, Finland 
Supervisor for PhD studies: Meike Römer, Jyrki Heinämäki, 2008, Finland 
Supervisor for PhD studies: Natalja Genina, Jyrki Heinämäki, 2010, Finland 
Supervisor for PhD studies: Satu Lakio, Jyrki Heinämäki, 2010, Finland 
Jouni Hirvonen ,  
Free the captured knowledge – Expertise and its development in the field of pharmacy, Jouni Hirvonen, 2005 
Caco-2 cell cultures in the assessment of intestinal absorbtion: Effects of some co-administered drugs and natural compounds in 
biological matrices, Jouni Hirvonen, 2006 
Studies on thermosensitive poly(N-vinylcaprolactam) based polymers for pharmaceutical applications, Jouni Hirvonen, 2007 
Characterization of ion-exchange fibers for controlled drug delivery, Jouni Hirvonen, 2008 
Preparation and characterization of poly(lactic acid) nanoparticles for pharmaceutical use, Jouni Hirvonen, 2008 
The Caco-2 cell line in studies of drug metabolism and efflux, Jouni Hirvonen, 2009 
Mechanistic Studies of Drug Dissolution Testing - Implications of solid phase properties and in vivo prognostic media, Jouni Hirvonen, 
2010 
Miniaturization of drug solubility and dissolution testings, Jouni Hirvonen, 2010 
Anne Juppo ,  
Mentorship: Properties of stabilizers in colloidal dispersions, Anne Juppo, 1999  2005, Sweden 
Ph.D. supervision: Characterisation and processing of amorphous binary mixtures with low glass transition temperature, Anne Juppo, 
2004  2008 
PhD supervision: Granulation in miniaturised fluid bed using electrostatic atomisation, Anne Juppo, 2006  2010, Finland 
Melting behaviour and quantification of low amorphous levels in sugars and sugar alcohols with DSC techniques, Anne Juppo, 2010 
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Leena Peltonen ,  
Supervisor for PhD studies, Leena Peltonen, 02.2008, Finland 
Supervisor for PhD studies, Leena Peltonen, 02.2010, Finland 
supervisor for PhD student, Leena Peltonen, 06.2010, Finland 
Jukka Tapio Rantanen ,  
Supervision of Doctoral thesis: Anna von Bonsdorff-Nikander, Jukka Tapio Rantanen, 2005 
Supervision of Doctoral thesis: Sari Airaksinen, Jukka Tapio Rantanen, 2005 
Niklas Sandler ,  
Supervision of Doctoral thesis: Fang Tian, Niklas Sandler, 2007, New Zealand 
Supervision of Doctoral thesis: Kivikero Niina, Niklas Sandler, 2010 
Mia Siven ,  
Supervision of Doctoral thesis, Mia Siven, 2006  …, Finland 
Supervisor for Doctoral thesis: Rosenqvist Kirsi, Mia Siven, 2007  … 
Clare Strachan 
PhD supervision, Clare Strachan, 2005  2008 
PhD supervision, Clare Strachan, 2006  2009 
PhD supervision, Clare Strachan, 2006  2008, New Zealand 
PhD supervision, Clare Strachan, 2006  2008 
PhD supervision, Clare Strachan, 2006  2008 
Jouko Yliruusi ,  
Supervison of Doctoral Thesis, Jouko Yliruusi, 2005 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2005 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2006 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2007 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2007 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2008 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2008 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2008 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2008 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2008 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2009 
Supervison of Doctoral Thesis, Jouko Yliruusi, 2010 
Supervison of PhD thesis, Jouko Yliruusi, 2010 
Prizes and awards 
Hélder A. Santos ,  
Stipends for accelerated completion of all postgraduate courses, Licentiate and Doctoral degrees (cum laude), Hélder A. Santos, 2003 
 2007, Finland 
Chancellor’s Travel grant, Hélder A. Santos, 2008, Finland 
Travel grant, Hélder A. Santos, 2008, Germany 
Formal tribute of Câmara Munincipal de Tarouca to Dr. Hélder A. Santos for the Award in the “Prémio Talento 2009” (Science Talent 
Award 2009), Hélder A. Santos, 29.07.2010, Portugal 
Talent Award 2009 in Science, Hélder A. Santos, 23.07.2010, Portugal 
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Top Reviewer in Pharmaceutical Sciences 2010 - ELSEVIER, Hélder A. Santos, 2010 
Travel grant, Hélder A. Santos, 2010, Finland 
Jouni Hirvonen ,  
University of Helsinki Quality Teaching Unit, Faculty of Pharmacy, Jouni Hirvonen, 2005, Finland 
CRS/Eurand Grand Prize Award on Innovations in Oral Drug Delivery Technologies, Jouni Hirvonen, 07.2007  …, United States 
University of Helsinki Quality Teaching Unit, Faculty of Pharmacy, Jouni Hirvonen, 2007  2009, Finland 
National Centre of Excellence in University Education, Faculty of Pharmacy, Jouni Hirvonen, 2010  2012, Finland 
Timo Laaksonen ,  
Gust. Komppa Award, Timo Laaksonen, 01.12.2008 
Satu Lakio ,  
Young Investigator Award, Satu Lakio, 08.06.2009, France 
Leena Peltonen ,  
Marques who's who in science and engineering, Leena Peltonen, 2008  … 
Top Reviewer in Pharmaceutical Sciences 2010, Elsevier, Leena Peltonen, 2010 
Jukka Tapio Rantanen ,  
Prizes, Jukka Tapio Rantanen, 2005 
Niklas Sandler ,  
AstraZeneca UK/US innovation award, Niklas Sandler, 2008 
Jouko Yliruusi ,  
Invited Professor, Jouko Yliruusi, 2005 
EUFEPS research award, Jouko Yliruusi, 2008, Switzerland 
Albert Wuokko award, Jouko Yliruusi, 2009 
Honorary Member of Finnish Society of Physical Pharmacy, Jouko Yliruusi, 2009 
Jaakko Aaltonen ,  
PhD Research Award, Jaakko Aaltonen, 2007 
Inna Miroshnyk ,  
Travel Grant, Inna Miroshnyk, 2005, Finland 
Chancellor's Travel Grant, Inna Miroshnyk, 2008, Finland 
Doctoral Dissertation Grant, Inna Miroshnyk, 2008, Finland 
Doctoral Dissertation Grant, Inna Miroshnyk, 2008, Finland 
The Best Poster Award, Inna Miroshnyk, 11.06.2008, Finland 
Doctoral Dissertation Grant, Inna Miroshnyk, 2009, Finland 
Chancellor's Travel Grant, Inna Miroshnyk, 2010, Finland 
Postdoctoral Grant for Research Abroad, Inna Miroshnyk, 16.03.2010, Finland 
Anne Soikkeli ,  
Young Investigator Poster Award, Anne Soikkeli, 20.04.2007, Netherlands 
Editor of research journal 
Jyrki Heinämäki ,  
AAPS Journal, Jyrki Heinämäki, 01.01.2005  31.12.2005 
Biopolymers, Jyrki Heinämäki, 01.01.2005  31.12.2005 
Carbohydrate Research, Jyrki Heinämäki, 01.01.2005  31.12.2005 
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Colloids and Surfaces B: Biointerfaces, Jyrki Heinämäki, 01.01.2005  31.12.2005 
European Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 01.01.2005  31.12.2005 
Journal of Food Engineering, Jyrki Heinämäki, 01.01.2005  31.12.2005 
Polymer International, Jyrki Heinämäki, 01.01.2005  31.12.2005 
AAPS Journal, Jyrki Heinämäki, 01.01.2006  31.12.2006 
European Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 01.01.2006  31.12.2006 
Acta Pharmaceutica, Jyrki Heinämäki, 01.01.2007  31.12.2007, Croatia 
Jouni Hirvonen ,  
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 2001  2010 
DOSIS, Jouni Hirvonen, 2003  2010 
Biomacromolecules, Jouni Hirvonen, 01.01.2005  31.12.2005 
Dosis, Jouni Hirvonen, 01.01.2005  31.12.2005, Finland 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2005  31.12.2005 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2005  31.12.2005 
International Journal of Pharmaceutics, Jouni Hirvonen, 01.01.2005  31.12.2005 
Journal of Controlled Release, Jouni Hirvonen, 01.01.2005  31.12.2005 
Pharmacutical Research, Jouni Hirvonen, 01.01.2005  31.12.2005 
Dosis, Jouni Hirvonen, 01.01.2006  31.12.2006, Finland 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2006  31.12.2006 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2006  31.12.2006 
International Journal of Pharmaceutics, Jouni Hirvonen, 01.01.2006  31.12.2006 
Journal of Controlled Release, Jouni Hirvonen, 01.01.2006  31.12.2006 
Biomacromolecules, Jouni Hirvonen, 01.01.2007  31.12.2007 
Dosis, Jouni Hirvonen, 01.01.2007  31.12.2007, Finland 
Duodecim, Jouni Hirvonen, 01.01.2007  31.12.2007 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2007  31.12.2007 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2007  31.12.2007 
International Journal of Pharmaceutics, Jouni Hirvonen, 01.01.2007  31.12.2007 
Journal of Controlled Release, Jouni Hirvonen, 01.01.2007  31.12.2007 
Journal of Cosmetic Dermatology, Jouni Hirvonen, 01.01.2007  31.12.2007 
Journal of Drug Delivery Science and Technology, Jouni Hirvonen, 01.01.2007  31.12.2007 
Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2007  31.12.2007 
Pharmaceutical Research, Jouni Hirvonen, 01.01.2007  31.12.2007 
Acta Biomaterialia, Jouni Hirvonen, 01.01.2008  31.12.2008 
Bioanalysis, Jouni Hirvonen, 01.01.2008  31.12.2008 
Dosis, Jouni Hirvonen, 01.01.2008  31.12.2008, Finland 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2008  31.12.2008 
European Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2008  31.12.2008 
International Journal of Pharmaceutics, Jouni Hirvonen, 01.01.2008  31.12.2008 
Journal of Controlled Release, Jouni Hirvonen, 01.01.2008  31.12.2008 
Journal of Pharmaceutical Sciences, Jouni Hirvonen, 01.01.2008  31.12.2008 
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Journal of Solid State Chemistry, Jouni Hirvonen, 01.01.2008  31.12.2008 
Pharmaceutical Research, Jouni Hirvonen, 01.01.2008  31.12.2008 
Powder Technology, Jouni Hirvonen, 01.01.2008  31.12.2008 
The Open Drug Delivery Journal, Jouni Hirvonen, 01.01.2008  31.12.2008 
Leena Peltonen ,  
Pharma Technology, Leena Peltonen, 01.01.2005  … 
Journal of Drug Delivery Science and Technology, Leena Peltonen, 01.01.2008  … 
Jukka Tapio Rantanen ,  
Member of the editorial board, Jukka Tapio Rantanen, 2005  … 
Niklas Sandler ,  
Member of the Editorial Board for Journal of Excipients and Food Chemicals, Niklas Sandler, 2009  … 
Peer review of manuscripts 
Sari Airaksinen ,  
Review of manuscripts, Sari Airaksinen, 2006  2007 
Hélder A. Santos ,  
Journal of Physical Chemistry B, Hélder A. Santos, 2005  … 
Langmuir, Hélder A. Santos, 2005  … 
Drug Discovery Today, Hélder A. Santos, 2008  … 
Journal of Nano Research, Hélder A. Santos, 2008  … 
European Journal of Pharmaceutical Sciences, Hélder A. Santos, 2009  … 
Journal Biomedical Chromatography, Hélder A. Santos, 2009  … 
Journal of Controlled Release, Hélder A. Santos, 2009  … 
The Leverhulme Trust, UK, Hélder A. Santos, 2009  … 
Colloids and Surfaces B: Biointerfaces, Hélder A. Santos, 2010  … 
International Journal of Pharmaceutics, Hélder A. Santos, 2010  … 
Particle and Fibre Toxicology, Hélder A. Santos, 2010  … 
Jyrki Heinämäki ,  
Reviewer in AAPS Journal, Jyrki Heinämäki, 1991  … 
Rewiever in Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 1991  … 
Reviewer in AAPS PharmSciTech, Jyrki Heinämäki, 1999  … 
Reviewer in AAPS PharmSciTech, Jyrki Heinämäki, 1999  … 
Reviewer in AAPS journal, Jyrki Heinämäki, 1999  … 
Reviewer in Acta Pharmaceutica, Jyrki Heinämäki, 1999  … 
Reviewer in Agricultural and Food Science, Jyrki Heinämäki, 1999  … 
Reviewer in Biopolymers, Jyrki Heinämäki, 1999  … 
Reviewer in Carbohydrate Research, Jyrki Heinämäki, 1999  … 
Reviewer in Carbohydrate research, Jyrki Heinämäki, 1999  … 
Reviewer in Colloids and Surfaces: biointerfaces, Jyrki Heinämäki, 1999  … 
Reviewer in Drug Development and Industrial Pharmacy, Jyrki Heinämäki, 1999  … 
Reviewer in European Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 1999  … 
Reviewer in European Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 1999  … 
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Reviewer in International Journal of Pharmaceutics, Jyrki Heinämäki, 1999  … 
Reviewer in International Journal of Pharmaceutics, Jyrki Heinämäki, 1999  … 
Reviewer in Journal of Food Engineering, Jyrki Heinämäki, 1999  … 
Reviewer in Journal of Pharmaceutical Sciences, Jyrki Heinämäki, 1999  … 
Reviewer in Journal of Pharmaceutical and Biomedical Analysis, Jyrki Heinämäki, 1999  … 
Reviewer in Journal of Pharmaceutical and Biomedical Analysis, Jyrki Heinämäki, 1999  … 
Reviewer in Polymer International, Jyrki Heinämäki, 1999  … 
Reviewer in STP Pharma Sciences, Jyrki Heinämäki, 1999  … 
Anne Juppo ,  
Drug Development and Industrial Pharmacy, Anne Juppo, 1996  2010 
European Journal of Pharmaceutics and Biopharmaceutics, Anne Juppo, 1996  2010 
European Journal of Pharmaceutical Sciences, Anne Juppo, 1999  2010 
Powder Technology, Anne Juppo, 2003  2010 
Journal of Controlled Release, Anne Juppo, 2004  2010 
Handbook of Pharmaceutical Excipients, Anne Juppo, 2007  2010 
Journal of Drug Delivery Science and Technology, Anne Juppo, 2007  2010 
Journal of Pharmaceutical Sciences, Anne Juppo, 2007  2010 
Timo Laaksonen ,  
Chemical Physics Letters, Timo Laaksonen, 2007 
Journal of Electroanalytical Chemistry, Timo Laaksonen, 2008 
Powder Technology, Timo Laaksonen, 2008  … 
Biomaterials, Timo Laaksonen, 2009  … 
Journal of the American Chemical Society, Timo Laaksonen, 2009  … 
The Journal of Physical Chemistry, Timo Laaksonen, 2009  … 
European Journal of Pharmaceutical Sciences, Timo Laaksonen, 2010  … 
Satu Lakio ,  
Käsikirjoitusten vertaisarviointi International Journal of Pharmaceutics -julkaisussa, Satu Lakio, 01.01.2007  31.12.2010 
Leena Peltonen ,  
European journal of pharmaceutical sciences, Leena Peltonen, 2001  … 
Journal of controlled release, Leena Peltonen, 2004  … 
Colloid and polymer science, Leena Peltonen, 2006 
European journal of pharmaceutics and biopharmaceutics, Leena Peltonen, 2006  … 
International journal of pharmaceutics, Leena Peltonen, 2006  … 
Nanomedicine, Leena Peltonen, 2007 
Cyclodextrins in the pharmacetucial and biomedical fields, Leena Peltonen, 2008 
Journal of pharmaceutical and biomedical analysis, Leena Peltonen, 2008 
Asian journal of pharmaceutics, Leena Peltonen, 2009  … 
Journal of drug delivery science and technology, Leena Peltonen, 2009  … 
African journal of biotechnology, Leena Peltonen, 2010  … 
BioDrugs, Leena Peltonen, 2010  … 
Chemical engineering journal, Leena Peltonen, 2010  … 
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Niklas Sandler ,  
Review of manuscripts, Niklas Sandler, 2003  … 
Mia Siven ,  
European Journal of Pharmaceutical Sciences, Mia Siven, 2004  2011 
Journal of Controlled Release, Mia Siven, 2004  2011 
Journal of Pharmacy and Pharmacology, Mia Siven, 2004  2005 
Reviewer in scientific journals, Mia Siven, 2004  … 
Journal of Applied Polymer Science, Mia Siven, 2005  … 
Pharmaceutical Research, Mia Siven, 2006  … 
Clare Strachan 
AAPS Journal, Clare Strachan, 2006  … 
AAPS PharmSciTech, Clare Strachan, 2006  … 
Analytica Chimica Acta, Clare Strachan, 2006  … 
Analytical Chemistry, Clare Strachan, 2006  … 
Applied Spectroscopy, Clare Strachan, 2006  … 
Energy and Fuels, Clare Strachan, 2006  … 
European Journal of Pharmaceutical Sciences, Clare Strachan, 2006  … 
European Journal of Pharmaceutics and Biopharmaceutics, Clare Strachan, 2006  … 
International Journal of Pharmaceutics, Clare Strachan, 2006  … 
Journal of Controlled Release, Clare Strachan, 2006  … 
Journal of Drug Delivery Science and Technology, Clare Strachan, 2006  … 
Journal of Pharmaceutical Sciences, Clare Strachan, 2006  … 
Journal of Pharmaceutical and Biomedical Analysis, Clare Strachan, 2006  … 
Journal of Pharmacy and Pharmacology, Clare Strachan, 2006  … 
Journal of Raman Spectroscopy, Clare Strachan, 2006  … 
Journal of the American Chemical Society, Clare Strachan, 2006  … 
Molecular Pharmaceutics, Clare Strachan, 2006  … 
Pharmaceutical Research, Clare Strachan, 2006  … 
Talanta, Clare Strachan, 2006  … 
Jaakko Aaltonen ,  
European Journal of Pharmaceutical Sciences, Jaakko Aaltonen, 2007  … 
European Journal of Pharmaceutics and Biopharmaceutics, Jaakko Aaltonen, 2007  … 
Instrumentation Science &amp; Technology, Jaakko Aaltonen, 2007  … 
International Journal of Pharmaceutics, Jaakko Aaltonen, 2007  … 
Journal of Chemometrics, Jaakko Aaltonen, 2007  … 
Journal of Pharmaceutical Sciences, Jaakko Aaltonen, 2007  … 
Journal of Pharmaceutical and Biomedical Analysis, Jaakko Aaltonen, 2007  … 
Journal of Pharmacy and Pharmacology, Jaakko Aaltonen, 2007  … 
Pharmaceutical Development and Technology, Jaakko Aaltonen, 2007  … 
Inna Miroshnyk ,  
Pharmaceutical Research, Inna Miroshnyk, 2004  … 
 
 
PARTICLE/Yliruusi 
 
 
9 
 
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE 
UNIVERSITY OF HELSINKI  
 
RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010 
 
 
Crystal Growth &amp; Design, Inna Miroshnyk, 2006  … 
Journal of Pharmaceutical Sciences, Inna Miroshnyk, 2007  … 
Bioorganic and Medicinal Chemistry, Inna Miroshnyk, 2008  … 
Journal of Pharmaceutical and Biomedical Analysis, Inna Miroshnyk, 2008  … 
Molecular Pharmaceutics, Inna Miroshnyk, 2008  … 
Pharmaceutical Development and Technology, Inna Miroshnyk, 2008  … 
Chemical Engineering Research and Design, Inna Miroshnyk, 2009  … 
International Journal of Pharmaceutics, Inna Miroshnyk, 2009  … 
Editor of series 
Clare Strachan 
Editorial board member, Clare Strachan, 2007  … 
Editor of special theme number 
Hélder A. Santos ,  
In Vitro Models Used in Drug Discovery: Drug Absorption and Metabolism, Hélder A. Santos, 09.2010  12.2011 
Innovative Technology for Drug Delivery Applications: From Nanocapsules and Biopolymers to Inorganic Materials, Hélder A. Santos, 
05.2010  04.2011 
Anne Juppo ,  
Dosis: Diversity of dosage form research - molecular, nano, micro and macro perspective, Anne Juppo, 2008, Finland 
Jaakko Aaltonen ,  
Special Issue Editor, Jaakko Aaltonen, 2010  2011 
Membership or other role in review committee 
Anne Juppo ,  
Referee of research project grant proposal in FWO-Vlaanderen, Anne Juppo, 2009, Belgium 
Jouko Yliruusi ,  
Evaluation of the Undergraduate Program at the Aristotle University of Thessaloniki, Jouko Yliruusi, 2008, Greece 
Evaluation of a company’s research funding application, Jouko Yliruusi, 2010, Estonia 
Membership or other role in research network 
Jouni Hirvonen ,  
Head of the early ADME group, Viikki Drug Discovery Technology Center, Jouni Hirvonen, 2000  2005, Finland 
Anne Juppo ,  
Pharmaceutical Solid State Research Cluster, Anne Juppo, 2006  2012 
Sinpharma/Nordpharma, Anne Juppo, 2007  2008 
Director of Pharmaceutical Solid State Research Cluster, Anne Juppo, 2010  2012 
Jouko Yliruusi ,  
Head of Division, Jouko Yliruusi, 1993  … 
National Graduate School in Natural Polymers, Jouko Yliruusi, 2008  … 
Membership or other role in national/international committee, council, board 
Hélder A. Santos ,  
Editorial Advisory Board Member, Hélder A. Santos, 2010  …, United States 
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Jyrki Heinämäki ,  
Board member, Finnish Pharmaceutical Society, Jyrki Heinämäki, 2002  … 
Suomen farmaseuttinen yhdistys (SFY), Jyrki Heinämäki, 01.01.2005  31.12.2005 
Suomen farmaseuttinen yhdistys (SFY), Jyrki Heinämäki, 01.01.2006  31.12.2006 
Invited reviewer, Jyrki Heinämäki, 2009, Belgium 
Jouni Hirvonen ,  
AAPS, Jouni Hirvonen, 1990  2011, United States 
Physical Pharmacy Federation, Jouni Hirvonen, 1996  2011, Finland 
European Pharmaceutical Federation, Jouni Hirvonen, 2001  2011, Sweden 
National ADME Cluster in Finland, Jouni Hirvonen, 2001  2007, Finland 
European Association of the Faculties of Pharmacy, Jouni Hirvonen, 2004  2011, Belgium 
Viikki Learning Centre, Jouni Hirvonen, 2004  2005, Finland 
Controlled Release Society, Nordic Chapter, Jouni Hirvonen, 01.01.2005  31.12.2005 
Finnish Pharmaceutical Association, Jouni Hirvonen, 2005  2011, Finland 
Controlled Release Society, Jouni Hirvonen, 2007  2011, United States 
Controlled Release Society Nordic Chapter, Jouni Hirvonen, 01.01.2007  31.12.2007, United States 
Controlled Release Society Nordic Chapter, Jouni Hirvonen, 01.01.2008  31.12.2008, United States 
Federation Pharmaceutiche International, Jouni Hirvonen, 2008  2011, Netherlands 
Board, Drug Policy 2020 in Finland, Ministry of Health, Jouni Hirvonen, 2010, Finland 
Pharmacopoeia Committee, Finnish Medicines Agency FIMEA, Jouni Hirvonen, 2010  2013, Finland 
Anne Juppo ,  
Representative in European Federation of Chemical Engineering (EFCE), Working Party on Agglomeration, Anne Juppo, 2001  2011 
Inspector (inspehtori) of Pharmacy Students Organisation in University of Helsinki, Anne Juppo, 2006  2012, Finland 
Member of the national committee on planning of specialising studies on Industrial Pharmacy, Retail Pharmacy and Hospital Pharmacy, 
Anne Juppo, 2006  …, Finland 
Member of the APV Focus Group in Veterinary Formulations, Anne Juppo, 2010  … 
Leena Peltonen ,  
Finnish Pharmaceutical Association, Leena Peltonen, 01.04.2004  … 
Slovenian Research Agency, Leena Peltonen, 01.01.2007  31.12.2007, Slovenia 
Niklas Sandler ,  
Member of the International steering committee, Niklas Sandler, 2008  …, United Kingdom 
Jouko Yliruusi ,  
Member of the Board of Graduate School in Pharmaceutical Research, Jouko Yliruusi, 1997  2010 
Member of the Board of Viikki Drug Discovery Technology Center, Jouko Yliruusi, 2000  2005 
Member of the Faculty Board, Jouko Yliruusi, 2004  2006 
Innovative Medicines Initiative, Contact Group Member, Jouko Yliruusi, 2005  2007 
Member of the Faculty Board, Jouko Yliruusi, 2010  … 
Membership or other role in public Finnish or international organization 
Sari Airaksinen ,  
Scientific advisor and consultant, Sari Airaksinen, 2006  …, Finland 
Hélder A. Santos ,  
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Membership, Hélder A. Santos, 2007  …, Switzerland 
Membership, Hélder A. Santos, 2008  …, United States 
Membership, Hélder A. Santos, 2008  …, Finland 
Membership, Hélder A. Santos, 2008  …, Finland 
Membership, Hélder A. Santos, 2010  …, Finland 
Membership, Hélder A. Santos, 2010  …, Italy 
Membership, Hélder A. Santos, 2010  …, United Kingdom 
Membership, Hélder A. Santos, 2010  …, Finland 
Jyrki Heinämäki ,  
Scientific advisor, Jyrki Heinämäki, 1995  …, Finland 
Scientific advisor, Jyrki Heinämäki, 1995  … 
Scientific advisor, Jyrki Heinämäki, 1995  … 
Scientific advisor and consultant, Jyrki Heinämäki, 1995  …, Finland 
Scientific advisor and consultant, Jyrki Heinämäki, 1995  …, Finland 
Scientific advisor and consultant, Jyrki Heinämäki, 1995  …, Finland 
Lääkelaitos, Jyrki Heinämäki, 01.01.2005  31.12.2005, Finland 
Lääkelaitos, Jyrki Heinämäki, 01.01.2006  31.12.2006, Finland 
Lääkelaitos, Jyrki Heinämäki, 01.01.2007  31.12.2007, Finland 
Jouni Hirvonen ,  
Member of the University committee of developing and implementing student feedback systems, Jouni Hirvonen, 2007  2008, Finland 
Opiskelijapalautejärjestelmän kehittämistyöryhmä, Jouni Hirvonen, 01.01.2007  31.12.2007, Finland 
Opiskelijavalintajärjestelmän kehittämistyöryhmä, Jouni Hirvonen, 01.01.2007  31.12.2007, Finland 
HUS Apteekin johtokunta, Jouni Hirvonen, 01.01.2008  31.12.2008, Finland 
HY:n piskelijapalautejärjestelmän kehittämistyöryhmä, Jouni Hirvonen, 01.01.2008  31.12.2008, Finland 
Jouko Yliruusi ,  
Honorary Member of Society of Physical Pharmacy in Finland, Jouko Yliruusi, 1988  … 
Member of Finnish Society for Natural Philosophy, Jouko Yliruusi, 1990  … 
Member of AAPS, American Association of Pharmaceutical Sciences, Jouko Yliruusi, 1993  … 
Member of AAAS, American Association for the Advancement of Science, Jouko Yliruusi, 2000  … 
Founder Member of Pharmaceutical Solid State Research Cluster (PSSRC), Jouko Yliruusi, 2006 
Member of Finnish Pharmaceutical Society, Jouko Yliruusi, 2007  … 
Inna Miroshnyk ,  
Membership, Inna Miroshnyk, 2001  …, Finland 
Membership, Inna Miroshnyk, 2002  …, Finland 
Membership, Inna Miroshnyk, 2002  …, Canada 
Membership, Inna Miroshnyk, 2003  …, Finland 
Membership, Inna Miroshnyk, 2009  …, United States 
Other tasks of an expert in private sector 
Inna Miroshnyk ,  
Consultant, Inna Miroshnyk, 2009  …, Finland 
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Participation in interview for written media 
Hélder A. Santos ,  
Homenagem da Câmara de Tarouca a um Ilustre Jovem Tarouquense (in Portuguese), Hélder A. Santos, 04.08.2010, Portugal 
Hélder Santos Homenageado na Terra Natal (in Portuguese), Hélder A. Santos, 04.08.2010, Portugal 
Tarouca Projectada Mundialemnte no Campo da Ciência (in Portuguese), Hélder A. Santos, 31.07.2010, Portugal 
Jyrki Heinämäki ,  
Hämeenlinnan seudun apteekkien koulutustilaisuus, Jyrki Heinämäki, 04.12.2002  31.12.2011, Finland 
Lääkevalmistus apteekissa -kurssi, Lääkehuollon täydennyskoulutuskeskus, Jyrki Heinämäki, 22.05.2002  31.12.2011, Finland 
Anne Juppo ,  
Kuljetuksen aikana jäätyneet lääkkeet voivat olla vaarallisia, Anne Juppo, 05.04.2007 
Lääkkeiden vaikutusten tutkiminen lapsilla tulee pakolliseksi, Anne Juppo, 10.01.2007, Finland 
Lääkkeitä lapsille, Anne Juppo, 2009, Finland 
Participation in TV programme 
Hélder A. Santos ,  
“Prémio Talento 2009” (Science Talent Award 2009), in Portuguese, Hélder A. Santos, 23.07.2010, Portugal 
Participation in interview for web based media 
Hélder A. Santos ,  
Portugal awards a citizen who is creating a science career in Finland, Hélder A. Santos, 29.09.2010, Finland 
Anne Juppo ,  
Yhteisellä asialla: Lääkkeitä lapsille, Anne Juppo, 2009, Finland 
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Web of Science(WoS)-based bibliometrics of the RC’s publications data 1.1.2005-31.12.2010  
by CWTS, Leiden University, the Netherlands 
Research Group: Yliruusi J 
Basic statistics 
Number of publications (P) 142 
Number of citations (TCS) 759 
Number of citations per publication (MCS)   5.35 
Percentage of uncited publications 28% 
Field-normalized number of citations per publication (MNCS)    .93 
Field-normalized average journal impact (MNJS)   1.14 
Field-normalized proportion highly cited publications (top 10%)    .74 
Internal coverage    .79 
 
Trend analyses 
 
MNCS 
 
THCP10 
 
MNJS 
Collaboration 
 
Performance (MNCS) by collaboration type 
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